BPG is committed to discovery and dissemination of knowledge
Review Open Access
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 125273
Published online Nov 15, 2026. doi: 10.4251/wjgo.125273
Inflammation-driven carcinogenesis in ulcerative colitis: Molecular and immunological pathways
Paulina Delgado-Gonzalez, Adriana G Quiroz-Reyes, Verónica L Loaiza-Gutiérrez, Elsa N Garza-Treviño, Department of Biochemistry and Molecular Medicine, School of Medicine, Universidad Autonoma de Nuevo Leon, Monterrey 64460, Nuevo León, Mexico
Mario A Simental-Mendía, Orthopedic Trauma Service, University Hospital Dr. José Eleuterio González, School of Medicine, Universidad Autonoma de Nuevo Leon, Monterrey 64460, Nuevo León, Mexico
ORCID number: Paulina Delgado-Gonzalez (0000-0002-0492-7968); Adriana G Quiroz-Reyes (0000-0002-9405-7483); Mario A Simental-Mendía (0000-0002-7179-494X); Verónica L Loaiza-Gutiérrez (0009-0005-5057-9326); Elsa N Garza-Treviño (0000-0002-1042-4603).
Co-corresponding authors: Paulina Delgado-Gonzalez and Elsa N Garza-Treviño.
Author contributions: Delgado-González P supervised and directed the development of the manuscript; Quiroz-Reyes AG designed the tables and figures, conducted the literature analysis, and contributed to manuscript writing; Simental-Mendía MA analyzed the literature and contributed to manuscript writing Loaiza-Gutiérrez VL drafted the manuscript and designed the tables; Garza-Treviño EN critically reviewed, edited, and revised the manuscript; Delgado-González P and Garza-Treviño EN they contributed equally to this article, they are the co-corresponding authors of this manuscript; and all authors read and approved the final version of the manuscript.
AI contribution statement: Portions of this manuscript were edited using AI tools solely for language refinement. The authors carefully reviewed and verified all AI-assisted outputs and take full responsibility for the scientific content of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Paulina Delgado-Gonzalez, Research Assistant Professor, Department of Biochemistry and Molecular Medicine, School of Medicine, Universidad Autonoma de Nuevo Leon, s/n, Monterrey 64460, Nuevo León, Mexico. paulina.delgadogn@uanl.edu.mx
Received: July 3, 2026
Revised: July 21, 2026
Accepted: August 18, 2026
Published online: November 15, 2026
Processing time: 126 Days and 8 Hours

Abstract

Ulcerative colitis (UC) is a chronic inflammatory bowel disorder resulting from a genetic predisposition, environmental factors, and immune system dysfunction. Chronic mucosal inflammation is an established precursor of colitis-associated colorectal cancer; however, the molecular transition from persistent inflammation to neoplasia remains unclear. The pathogenesis of UC involves disruption of the intestinal barrier, resulting in dysregulated innate immune responses mediated by toll-like receptor signaling and NOD-like receptor family pyrin domain containing 3 inflammasome activation, followed by polarized adaptive responses mediated by T helper 2 and T helper 17 cells. Intestinal dysbiosis further influences immunity by facilitating DNA damage through oxidative stress and metabolic alterations. Mechanisms of immune evasion, including regulatory T-cell dysfunction and the activation of anti-apoptotic pathways such as Janus kinase/signal transducer and activator of transcription and nuclear factor kappa-light-chain-enhancer of activated B cells, perpetuate chronic inflammation. This pro-inflammatory environment, characterized by interleukin-6 and tumor necrosis factor alpha signaling, promotes genomic instability and establishes oncogenic conditions favorable for gastrointestinal malignancies. The transition from UC to cancer is sustained by microbe-induced inflammation and immune evasion. This review aims to synthesize current knowledge of the immunological and inflammatory mechanisms in UC, highlighting the functions of innate and adaptive immunity, dysbiosis, oxidative stress, and immune evasion, while also addressing how these findings contribute to biomarker identification and personalized therapeutic approaches in gastrointestinal oncology.

Key Words: Ulcerative colitis; Colorectal cancer; Bowel dysbiosis; Chronic inflammation; Immune evasion; Oxidative stress

Core Tip: Chronic inflammation in ulcerative colitis disrupts immune balance and gut microbiota, leading to reactive oxygen species production and driving molecular changes that foster colorectal cancer like cell growth, anti-apoptosis. This article synthesizes immunological, inflammatory, and molecular mechanisms in ulcerative colitis-associated carcinogenesis highlights risk factors such dysbiosis, biomarker identification, genomic instability, immune evasion and therapeutic implications for cancer prevention, while outlining future research directions to improve diagnostics and treatment.



INTRODUCTION

Ulcerative colitis (UC) is a chronic, nonspecific, and recurrent inflammatory bowel disease (IBD), primarily affecting the colon and rectum[1]. Symptoms include frequent bowel movements, mucus, bloody stools, pain, and weight loss[2]. Symptoms in the upper gastrointestinal tract, such as eosinophilic esophagitis, gastroduodenitis, and ulcers, are not frequently reported.

The symptoms of UC occur in relapses or what are known as flare-ups; they can be sudden and severe, causing diarrhea with mucus and blood, high fever, abdominal pain, and, occasionally, peritonitis (defined as inflammation of the lining of the abdominal cavity, causing intense pain throughout the abdomen).

Genetic predisposition, immune response, environmental factors, and dysregulation of the gut microbiota are recognized risk factors[3]. The condition is slightly more common in men, with the first onset occurring between the ages of 15 and 30. The relationship between UC and the development of colorectal cancer (CRC) has been extensively documented through multiple epidemiological studies over the past two decades. One of the landmark studies in this field is the meta-analysis by Eaden et al[4], published in 2001, which established a CRC incidence rate of 3 cases per 1000 person-years, along with a cumulative prevalence of 3.7% among UC patients. Years later, Jess et al[5] conducted a 2012 meta-analysis based on population-based cohorts, calculating a pooled standardized incidence ratio of 2.4, suggesting a considerably higher CRC risk compared with the general population. Similarly, the meta-analysis performed by Lutgens et al[6] in 2013, using cohorts with comparable characteristics, reported a pooled standardized incidence ratio of 1.7. Subsequently, Castaño-Milla et al[7] carried out a further meta-analysis in 2014 that revealed a decline in CRC incidence rate to 1.58 cases per 1000 person-years, suggesting a possible downward trend in risk over time, likely associated with improvements in endoscopic surveillance and therapeutic management of the disease.

Defects in the colonic microbiota and the epithelial barrier, along with an altered immune response evidenced by leukocyte recruitment, are part of the pathophysiology of UC[8]. The colonic epithelial barrier and the intestinal mucosa are considered complementary in the defense of the intestine; the epithelial barrier consists of a double layer of mucus and an epithelium that allows the absorption of water and electrolytes. The gastrointestinal mucosa facilitates nutrient absorption and immune detection while limiting the transport of harmful antigens and microorganisms responsible for inflammatory processes. Among the elements that confer its barrier function are an outer layer of mucus containing the commensal gut microbiota, antimicrobial proteins (AMPs), and secretory immunoglobulin A molecules. Immune cells such as T cells, B cells, macrophages, and dendritic cells reside in the lamina propria[9].

In UC, colonic mucin and the tight junctions of the epithelial barrier are compromised, leading to increased uptake of luminal antigens. The lamina propria of the mucosa contains an increased number of activated and mature dendritic cells, characterized by a high density of toll-like receptors (TLRs), specifically TLR2 and TLR4[10].

IMMUNE ESCAPE MECHANISMS

UC is a debilitating inflammatory disease characterized by T-cell-mediated inflammation, with microbial antigens likely serving as the initial immune stimuli, classifying UC as an autoimmune disease due to immune-mediated tissue damage[11,12].

There appears to be an atypical response by helper T (Th) cells in UC, specifically Th2 cells, which mount a cytotoxic response against epithelial cells. The pathogenic T cell subsets include interleukin (IL)-17 cytokine-producing CD4+ T cells (TH17) and CD8+ T cells, follicular helper CD4+ T cells, IL-26-producing CD8+ T cells, and granzyme K- and eomesodermin-expressing CD8+ T cells[13-15].

Other immune system-related factors involved in the pathophysiology of UC include tumor necrosis factor alpha (TNF-α), IL-13, and natural killer cells. Among immunoglobulins (Ig), an increase in IgG1 antibodies is observed in patients with UC.

In UC, there is increased release of the chemotactic factor C-X-C motif chemokine ligand (CXCL) 8, leading to the recruitment of leukocytes to the mucosa from the systemic circulation[16,17]. In addition, increased expression of the mucosal cell adhesion molecule-1 is observed in the endothelium of mucosal blood vessels, promoting the adhesion and extravasation of leukocytes into the mucosal tissue[18].

Changes in the commensal microbiota affect intestinal immune regulation (Table 1), leading, for example, to excessive production of proinflammatory cytokines such as IL-6, IL-12, and IL-23, as well as TNF-α in IBD such as UC and Crohn’s disease (CD)[19]. Studies have demonstrated a decrease in short-chain fatty acid-producing gut bacteria such as Faecalibacterium prausnitzii, Roseburia inulinivorans, and Ruminococcus torques in the stool of patients with IBD[20]. Likewise, an increase in pro-inflammatory, toxin-producing, adherent, and invasive bacteria such as Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, and Bacteroides fragilis has been observed[21-23]. A correlation has been found between the enrichment of bacterial species in UC and the modification of metabolic pathways involved in the degradation of amines and polyamines, which have also been reported to play a role in CRC.

Table 1 Gut microbiota and inflammatory bowel disease.
Intestinal
Bacteria
Bacterial loaded
Involved or altered metabolic pathway
Associated inflammatory disease
Immuno-modulatory effect
Ref
Faecalibacterium prausnitzii↓Butyrate synthesis. Mucus production promotionCD; UCInduces IL10RA-dependent claudin-2 suppression and promotes the differentiation of regulatory T cells[126]
Prevotella
(p. Ej. P. Copri)
Depending on the speciesFiber fermenter↑ incidence and complications of IBS and IBDInhibits the autoimmune response and maintains the intestinal barrier[127]
SCFAAssociated with systemic inflammation, altering the production of cytokines and regulatory T cells
Producer (propionate and acetate)
Bacteroides fragilis enterotoxigénic↑Beneficial gut bacteria that feed complex carbohydratesUCIt disrupts the immune response by promoting or exacerbating inflammation[128]
Toxicogenic strain, pro-inflammatory signaling, and disruption of the intestinal barrierActive IBD
CRC risk
Veillonella parvula↑Lactate-fermenting opportunistic pathogenic commensal bacteriumActive UCIncreases the permeability of epithelial cells in the colon by activating macrophages and producing pro-inflammatory factors[129]
Tyzzerella nexilis↑Commensal bacterium involved in the fermentation of indigestible carbohydrates and the synthesis SCFAIntestinal inflammationMobile genetic elements confer pathogenic properties and promote neuroinflammation[130]
Rothia mucilaginosa↑-IBDIncreases levels of circulating lymphocytes and correlates with the inflammatory marker calprotectin[131]
Blautia hansenii↓ in active diseaseSynthesis SCFA helps maintain the function of colonic mucus↓ in active diseasePrevent the adhesion of pathogenic bacteria[132]
Suppression of pro-inflammatory response
Akkermansia muciniphila↓Degrade the glycoprotein mucin as a source of carbon and nitrogenIBDReduces the levels of infiltrating macrophages in the colon and cytotoxic T cells[133]
Bifidobacterium spp.↓Fermentation of complex carbohydrates (fiber)CD; UCRegulates intestinal inflammation, promotes T-cell response, and strengthens the intestinal barrier[134]
Lactobacillus spp.↓Lactate synthesis, immune modulators, and intestinal barrier repairIBDIt regulates cytokine production and reduces the effects of TNF-α. It induces the production of B cells, NK cells, and Treg cells[135,136]
Enterococcus faecalis↑Biofilm formation, pro-inflammatory cytokines, and glucosamine metabolismIBD complicatedPathobiont behavior activates NF-κB and TLR inflammatory pathways[137]
FAILURE OF APOPTOSIS IN ACTIVATED LYMPHOCYTES IN UC

A central feature of UC pathogenesis is the abnormal handling of activated lymphocytes in the colonic mucosa; rather than being efficiently eliminated after antigen exposure, activated CD4+ T cells in the lamina propria acquire resistance to apoptosis and thereby accumulate, sustaining local cytokine production and tissue injury[24-26]. Recent mechanistic studies indicate that this phenomenon is not attributable to a single molecular defect, but rather to a network of dysregulated apoptotic pathways involving cytokines, survival proteins, and altered death-receptor signaling in activated mucosal T cells[11,26].

At the molecular level, UC mucosal T cells show upregulation of anti-apoptotic factors [for example, survivin and members of the B-cell lymphoma 2 (Bcl-2) family] and altered expression/function of death-receptor pathways (Fas/Fas-L, caspases)[27,28]. A translationally relevant example is that survivin expression is increased in CD4+ T cells from UC patients. Survivin forms complexes that interfere with transcriptional induction of Fas ligand and disrupt downstream apoptotic execution, thereby rendering activated T cells less susceptible to activation-induced cell death in vitro and in vivo[29]. This survivin-mediated apoptosis blockade provides a mechanistic explanation for persistent T-cell accumulation and is being explored as a potential therapeutic target[28].

Peripheral blood T cells and normal lamina propria T cells maintain a regulated balance of Bcl-2 family members, whereas UC-derived T cells exhibit altered expression patterns that favor survival[30]. Although earlier studies in IBD primarily described such differences in CD mucosa, the concept remains applicable to UC pathophysiology[30,31].

The tissue cytokine environment in UC may further embed apoptosis resistance. Local IL-6, IL-23 and type I/II interferons would activate signal transducer and activator of transcription (STAT) 3/nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathways and that would increase expression of BCL2 L1, the protein Bcl-xL and other anti-apoptotic effectors, while chronic TNF signaling has pleiotropic effects that may protect some immune subsets even while promoting epithelial cell death - thus twisting cell death away from resolution of inflammation and toward barrier disruption[32-34]. Tissue-resident memory T cells and altered co-stimulatory signaling (e.g., IL-2-inducible tyrosine kinase and other kinases) sustain survival and effector function of mucosal T cells; pharmacologic targeting of these pathways (for instance, IL-2-inducible tyrosine kinase inhibitors) can promote resolution in experimental colitis models, supporting the causal role of apoptosis resistance in disease perpetuation[27].

Consequences for the mucosal environment can be twofold: (1) Accumulation of long-lived, cytokine-producing T cells (Th1/Th2/Th17 skewing depending on context) perpetuates neutrophil recruitment, matrix degradation, and crypt damage[35-37]; and (2) Impaired apoptotic clearance limits immune regulation via tolerogenic antigen-presenting cell reprogramming and efferocytosis-driven resolution programs. Clinically, these mechanisms may help explain persistent mucosal inflammation despite therapy and rationalize strategies that either restore pro-apoptotic signaling in pathogenic T cells (target survivin, Bcl-2 family members, or death-receptor pathways) or selectively deplete pathogenic mucosal T-cell subsets[38,39]. However, balancing epithelial-versus immune-cell apoptosis remains a therapeutic challenge.

DEFECT IN REGULATORY T-CELL FUNCTION IN UC

Maintenance of intestinal immune tolerance depends critically on regulatory T cells (Tregs), particularly forkhead box P3 (FOXP3)+CD4+ Tregs, which suppress effector T-cell activity and limit tissue damage[40,41]. In UC, a defect not only in Treg numbers (particularly in peripheral blood and some mucosal compartments) but - crucially - in their functional capacity, lineage stability, and survival under inflammatory conditions[42]. A meta-analysis of IBD patient cohorts reported a significantly lower frequency of CD4+CD25+CD127- and CD4+CD25+FOXP3+ Tregs in the peripheral blood of IBD (including UC) patients compared to healthy controls - especially during active disease phases[43].

Beyond reduced frequency, functional impairment of Tregs in UC has been documented. A recent study using colon tissue from colitis models and humanized immune-colitis systems found altered expression of key functional molecules among Tregs and conventional CD4+ T cells in colitis, including increased expression of activation markers (e.g., inducible T cell costimulator, programmed cell death protein 1, T cell immunoreceptor with Ig and ITIM domains) and shifts in transcriptional regulators (e.g., BCL6) suggesting that compensatory expansions are insufficient to restore effective immune regulation[44]. Mechanistically, recent immunological advances highlight that Treg deficiencies in IBD are rooted in disrupted signaling, epigenetic maintenance, and metabolic control. Dysregulation of pathways, including IL-2/STAT5 signaling, mammalian target of rapamycin (mTOR) signaling, and epigenetic regulation at the FOXP3 conserved non-coding sequence 2 locus undermines Treg lineage stability, allowing Tregs to lose FOXP3 expression or acquire features of effector T cells[45]. This plasticity contributes to the loss of suppressive capacity and may even promote pro-inflammatory potential.

From a translational standpoint, these insights have already motivated therapeutic strategies: A recently published study demonstrated that adoptive transfer of autologous Tregs ameliorated colonic inflammation in a humanized mouse model of colitis, reducing T-cell infiltration and preserving colon architecture[46]. Studies in UC patients and experimental models document increased frequencies of IL-17+FOXP3+ CD4+ cells and other hybrid phenotypes; the functional consequences are context dependent (some IL-17+FOXP3+ cells retain suppressive activity, others do not), but overall this plasticity erodes regulatory control and may convert formerly regulatory cells into contributors to inflammation[47,48]. Moreover, a current reviews propose that future therapies might combine Treg expansion with interventions that stabilize FOXP3 expression (e.g., via metabolic modulators, epigenetic agents or cytokine signaling modulators), or block destabilizing signals such as IL-23 receptor[45].

MOLECULAR PATHWAYS

During bowel inflammation, chronic activation of inflammatory molecular pathways occurs even before dysplasia develops[49]. This leads to the establishment of a pro-tumorigenic microenvironment, following a sequence of genetic alterations involving increase of cell survivor, proliferation, and UC-associated CRC (UC-CRC) establishment[50]. Clinical and animal research have demonstrated a crucial role of pro-inflammatory pathways (Figure 1) such as NF-κB, IL-6/STAT3, cyclooxygenase 2/prostaglandin E2, and IL-23/Th17 in the pathogenesis of UC-CRC[49]. P53, KRAS, IDH15, and APC genes are significantly higher in UC-CRC. Moreover, deletion of P53 in colorectal epithelium accelerates replacement of pre-malignant stem cell during colitis, creating a permissive environment for tumor establishment[51].

Figure 1
Figure 1 Main signaling pathways and genes involved in the pathogenesis of ulcerative colitis and its progression to colitis-associated colorectal cancer. The inflammatory, immunological, and molecular mechanisms involved in epithelial barrier dysfunction, chronic intestinal inflammation, and neoplastic transformation are described. STAT3: Signal transducer and activator of transcription 3; NF-κβ: Nuclear factor kappa-light-chain-enhancer of activated B cells; IL-6: Interleukin-6; IL-11: Interleukin-11; SP1: Specificity protein 1; JAK: Janus kinase; TGFβ: Transforming growth factor beta; VEGF: Vascular endothelial growth factor; IKK: Complex an enzyme group made of subunits like Ikappa α, Ikappa β, and Ikappa γ; IKβ: Ikappa B kinase; COX-2: Cyclooxygenase-2; RTKs: Receptor tyrosine kinase; LPS: Lipopolysaccharide; TNF-α: Tumor necrosis factor alpha; PI3K: Phosphoinositide 3-kinase; Akt: Protein kinase B; ZO-1: Zonula occludens-1; MAPK: Mitogen-activated protein kinase; UC-CRC: Ulcerative colitis associated colorectal cancer; KRAS: Kirsten rat sarcoma viral oncogene homolog; IDH15: Isocitrate dehydrogenase 15; APC: Adenomatous polyposis coli; PI3KCA: Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; IRS1: Insulin receptor substrate 1; PI3KR1: Phosphoinositide-3-kinase regulatory subunit 1; PDK1: Pyruvate dehydrogenase kinase 1; AKT1: Serine/threonine kinase 1; AKT2: Serine/threonine kinase 2; PAK4: P21-activated kinase 4; mTOR: Mammalian target of rapamycin; PTEN: Phosphatase and tensin homolog; TSC1/2: Tuberous sclerosis complex subunit 1/2; SOCS: Suppressor of cytokine signaling; PIAS: Protein Inhibitor of Activated STAT; PTPs: Protein tyrosine phosphatases; mTORC1: Mechanistic target of rapamycin complex 1; ULK: Unc-51-like kinase; ROS: Reactive oxygen species; NLRP3: Nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain-containing protein 3; AMPK: AMP-activated protein kinase.
STAT3/NF-κB

STAT3 is involved in biological processes including cell proliferation, survival, differentiation, and angiogenesis[52], and also plays a role in regulating the antitumor immune response of Th17 cells. In intestinal epithelial cells, STAT3 regulates cell cycle by inducing the production of proteins such as Bcl-xL, survivin and heat shock protein 70, thereby inhibiting apoptosis and promoting proliferation[53]. Upregulation of sphingosine kinase 1 during colitis leads to increased sphingosine-1-phosphate, which activates IL-6/STAT3 and amplifies its loop[54].

During active UC, there is an increased STAT3 activation in intestinal epithelial cells. Hyperactivated STAT3 enhances cytokines and growth factors expression such as IL-6, IL-10, transforming growth factor β, and vascular endothelial growth factor, exerting immunological and inflammatory effects. IL-6 and IL-11 activate STAT3 by gp130, preventing enterocytes apoptosis and facilitating proliferation of intestinal epithelial cells[55].

In tumor cells, STAT3 interacts with other signaling pathways, such as NF-κB[56]. In UC, chronic inflammation causes aberrant NF-κB signaling in colonic epithelial cells and macrophages, promoting carcinogenesis[57] and disrupting antitumor immunity. NF-κB induces STAT3 by increasing transcription[53] of cyclooxygenase 2, IL-6, IL-23, and IL-1β, which are involved in chronic inflammation and oncogenesis. The STAT3-NF-κB interaction contributes to cancer development through co-activation in tumor cells and tumor microenvironment-associated infiltrating immune cells, sharing targets involved in cell proliferation, metastasis, anti-apoptosis, and angiogenesis; notably, IL-6 can simultaneously activate both STAT3 and NF-κB[58].

In CRC, STAT3 and NF-κB are hyperactivated in malignant cells and tumor-infiltrating leukocytes, promoting the proliferation and survival of cancer cells and driving pro-tumor inflammation[59]. Furthermore, NF-κB activation in tumor-associated macrophages has been shown to regulate the development and progression of CRC.

Phosphatidylinositol 3-kinase-protein kinase B

Phosphatidylinositol 3-kinases (PI3Ks) are intracellular lipid kinases involved in the regulation of cell proliferation, differentiation, and survival. Overexpression of the PI3K/protein kinase B (AKT)/mTOR pathway has been observed in several types of cancer, including CRC[60].

The PI3K/AKT axis causes alterations in tight junction proteins (e.g., zonula occludens and occludin), increasing intestinal permeability and allowing massive leakage and paracellular passage of antigens, bacterial toxins, and lipopolysaccharides into the lamina propria and deeper connective tissue, leading to deeper mucosal inflammation[61].

Under normal conditions, the PI3K/AKT signaling pathway is temporarily activated to repair the intestinal mucosa. It regulates the activation of inflammatory cells and the release of inflammatory mediators such as TNF-α, IL-1β, and IL-6, playing a clear role in immune inflammation and intestinal mucosal integrity in UC[62,63]. Chronic hyperactivation links the inflammatory damage of UC to the development of CRC, altering the T-cell immune response. The activation of NF-κB is dependent on IkB kinase; in the presence of TNF-α and IL-1, PI3K/AKT phosphorylates IkB kinase, thereby activating NF-κB signaling[53].

Dysregulated PI3K signaling drives CRC initiation and progression by disrupting cellular processes such as proliferation, cell growth, apoptosis, survival, and cytoskeletal reorganization[64]. Aberrant activation of the PI3K/AKT/mTOR pathway involves processes such as receptor tyrosine kinase activation and somatic mutation or amplification of genes encoding key enzymes, substrates, or regulators of the pathway, such as PI3KCA, insulin receptor substrate 1, PI3KR1, pyruvate dehydrogenase kinase 1, AKT1, AKT2, p21-activated kinase 4, and mTOR, or a loss of the tumor suppressor genes PTEN and TSC1/2[65].

Somatic frameshift mutations in the PI3K gene are common in approximately one-third of CRC cases during the adenoma-to-carcinoma transition[66].

Janus kinase-STAT

The Janus kinase (JAK) STAT pathway plays a critical role in immune system organization through cytokine receptors signaling, and can regulate the polarization and fate of CD4+ Th cells by differentiating them into Th1, Th2, Th17, and Tregs[67]. The role of JAK-STAT in active immune responses has been demonstrated, constituting a master regulator of immune cell homeostasis. Through JAK, IL-6 and IL-11 activate STAT3 transcription which participates in tumor-initiating intestinal epithelial cells[53].

In addition to its role in signal transduction, the JAK-STAT pathway plays a fundamental role in regulating various stress-induced cellular responses, such as hypoxia-reperfusion injury, the presence of endotoxins, ultraviolet radiation, and alterations in cellular osmolarity[68].

This pathway is regulated by various regulatory proteins, such as cytokine signaling suppressors, inhibitors of activated STAT proteins, and protein tyrosine phosphatases, which determine the initiation, duration, and termination of signaling cascades[69]. Aberrant JAK/STAT signaling contributes to UC by regulating the intestinal inflammatory response, affecting the intestinal mucosal barrier, modulating T-cell homeostasis, and influencing macrophages activity[70]. Expression levels of JAK2 and STAT3 is positively associated with the severity of IBD[71].

AMP-activated protein kinase

AMP-activated protein kinase (AMPK) is a central regulator of cellular energy homeostasis[72]. The utilized substrates include key enzymes and transcriptional regulatory factors involved in physiological processes such as autophagy, cell growth, proliferation, metabolism, and immune modulation[73,74].

Under normal physiological conditions, the AMPK pathway acts as a negative regulator of inflammation[75], however, in UC, aberrant expression of the AMPK pathway affects cellular metabolism, reduces autophagy, and exacerbates colonic inflammation. This mechanism is explained by the fact that factors such as infection, inflammation, and endoplasmic reticulum stress activate AMPK and inhibit the mTOR complex 1 (mTORC1), facilitating the initiation of autophagy through the activation of the Unc-51-like kinase complex[76].

Dysfunctional autophagy leads to impaired intestinal epithelial function, intestinal dysbiosis, altered secretion of antimicrobial peptides by Paneth cells, and atypical immune responses to pathogens in patients with UC[77].

Dysregulated AMPK also modulates oncogenic signaling through the mTORC1 pathway and contributes to malignant transformation by reprogramming nutrient acquisition and metabolic pathways to meet increasing bioenergetic and biosynthetic demands of cancer cells. Its effects are context-dependent, influencing tumor initiation, progression, metabolic adaptation, and therapeutic responses[78].

Mitogen-activated protein kinase and mTOR

Mitogen-activated protein kinase (MAPK) and mTOR are two intracellular signaling pathways. MAPK regulates cell division and survival, while the mTOR functions as a primary nutrient sensor that regulates cell growth and metabolism.

In response to triggers such as infections, toxins, oxidative stress (OS), and endoplasmic reticulum stress, the MAPK pathway becomes hyperactivated, stimulating macrophages and epithelial cells to produce proinflammatory cytokines like TNF-α and IL-6, thereby prolonging damage to the intestinal mucosa[79]. In UC, p38MAPK phosphorylation levels are elevated in colonic mucosal tissues[80]. MAPK can interact with short-chain fatty acids, lipopolysaccharides from the gut microbiota, and immune cells such as macrophages and Th17 cells, amplifying intestinal inflammatory[81].

In CRC, MAPK is typically activated by mutations in the KRAS, BRAF, or EGFR genes, leading to uncontrolled tumor growth and resistance to treatment. Upregulation of EGFR is a potential mechanism that contributes to pathway activation in this cancer[82]. MAPK has also been implicated in CRC metastasis, as semaphorin-3C protein secreted by tumor-associated fibroblasts binds to neuropilin 2 receptors on liver metastasis-initiating cells, promoting the activation of the MAPK-p38/JNK signaling pathway, which promotes liver metastasis and is associated with poor clinical outcomes[83].

In inflammatory conditions, mTOR overactivation interacts with mediators such as NF-κB and NLRP3 (inflammasome), triggering destructive cytokines and disrupts autophagy, accelerating the death of intestinal epithelial cells. mTORC1 is a central protein complex within the mTOR pathway; it is active in stem cells at the base of intestinal crypts, but is gradually silenced as transient amplifying cells differentiate into enterocytes or secretory cells throughout the epithelium[84].

Factors such as repeated stress or injury cause mTORC1 to become constitutively active, resulting in an irreversible return to pluripotency, cell division, proliferation, and inflammation in differentiated epithelial cells, making them susceptible to tumorigenesis[85].

BIOMARKERS FOR CANCER RISK PREDICTION

Understanding the pathological alterations during UC-CRC enables the identification of prognostic biomarkers that can distinguish chronic inflammation from early-stage carcinogenesis and improve cancer risk prediction[86]. However, even though numerous biomarkers have been identified, none of them is an effective or sufficient predictor of either the UC-CRC[87]. Table 2 summarizes current biomarkers for UC-CRC diagnosis and prognosis such as dysregulated genes, epigenetic alterations, microRNA (miRNA), circulating tumor cells, and exosomes, with their clinical relevance and limitations, A combination this approach is necessary for refined disease staging.

Table 2 A summary of tissue-based biomarkers identified in ulcerative colitis-colorectal cancer and their clinical relevance for screening.
Biomarker
Clinical relevance
Advantages/limitations
Ref.
TP5371% in low-grade dysplasia, 83% in high-grade dysplasia, 100% in adenocarcinoma; absent in uninvolved mucosaAdjunctive biomarker to identify high-risk patients before histologic changes occur, predicting risk of evolution toward malignancy[88,138-140]
p14ARF hypermethylation100% in dysplastic tissue vs 26% in non-dysplastic biopsiesPredictor of future dysplasia during surveillance[141,142]
1-8U gene (interferon-inducible) (IFITM3)High expression in cancer and severely inflamed and cancerous UC mucosa; absent in normal tissueDiscrimination of high-risk areas before visible dysplasia[143,144]
Telomere shortening + clonal expansions100% sensitivity, 80% specificity distinguishing progressors from non-progressors (early-onset UC)Risk stratification in young patients with extensive disease[145,146]
Associated with proximity to dysplasia
Aneuploidy (flow cytometry ploidy)5/6 patients with aneuploidy developed dysplasia in 1-2.5 years vs 0/19 without aneuploidyNot routinely implemented by insufficient prospective validation, and the growing emphasis on gene-specific genomic alterations[88,146-148]
Adjunctive marker in biopsies indefinite for dysplasia
Copy number variants (lpWGS-derived CNA score)Cumulative chromosomal alterations before advanced neoplasiaScalable, cost-effective tool to predict progression from low-grade dysplasia[88,149,150]
Lack of prospective multicenter validation, standardized analytical pipelines and cut-off values, and generalizability beyond low-grade dysplasia cohorts
miR-9 methylationIncreases with age, disease duration, proximity to cancerHigh-accuracy discrimination in rectal mucosa
Lack of independent prospective validation and evidence supporting its use only within multi-marker methylation panels
[88,151,152]
Methylation panel (SFRP2, SFRP4, WIF1, APC1A, APC2)Detects pre-cancerous and invasive neoplasiaValidated multiplex panel from a multicenter study (ENDCAP-C)
Limited by the need for colonic biopsy, only moderate prediction of neoplastic progression in non-neoplastic mucosa, and the transition toward genome-wide biomarkers (e.g., CNA profiling and lpWGS)
[153,154]
Stool microbiome
(16 rRNA sequencing)
Mucosal microbiota (Firmicutes/Bacteroidetes ratio) exhibit persistent dysbiosis UC-CRCPositive association between Fermicutes and Proteobacteria Bacteroidetes and inflammatory markers with incidence of CRC[155,156]
TP53-nuclear (IHC) + cytokeratin 7TP53 strong nuclear overexpression correlates with neoplastic progressionUseful adjunct when histology is ambiguous (indefinite for dysplasia)[157-159]
CK7 not expressed in normal colonic mucosa. Expressed in all cases of epithelial dysplasia, with no difference between moderate and severe dysplasia
miR-21, miR126, miR146b-5p and miR-223Upregulation in active UCNon-invasive disease monitoring[160]
miR-142-3p, miR-144-3p, and miR-193a-5pOverexpression in adenomas but down-regulated in CRCBiomarker pre-cancer[161]
miR-31, miR-135b and miR-106aTracking of malignant progression via expression profilingMucosal miRNAs that not only accurately discriminate dysplasia from normal mucosa but also indicate a higher risk of CRC and are expressed in UC-CRC[162,163]
ctDNA, circulating tumor cells, exosomes, tumor-educated plateletsReflect real-time molecular heterogeneityMinimally invasive surveillance complementary to colonoscopy[164]
Requires validation
KRAS mutationsOccur later, often co-occurring with TP53
Frequency of KRAS mutations increases continuously from non-dysplastic IBD colon to UC-CRC, and they are observed to be mutually exclusive with BRAF mutations
Limited clinical utility as a standalone biomarker[165]
Invisible lesions in patients without IBD exhibit fewer KRAS and APC mutations compared with polypoid lesions, but show a higher frequency of BRAF mutationsKRAS mutations were enriched in non-dysplastic UC colon at approximately 14%[166]

Molecular biomarkers in UC-CRC surveillance have shown promising associations with neoplastic progression, but they still present important limitations. Many, such as TP53 mutations, methylation patterns, or miRNA profiles, are detected in non-dysplastic mucosa and reflect the ‘field effect’; however, they lack prospective validation, and their sensitivity and specificity vary depending on the technique used. Moreover, disease heterogeneity, lesion multifocality, and the difficulty in distinguishing regenerative changes from dysplasia reduce their routine clinical applicability. Consequently, although these biomarkers complement colonoscopy and histology, they are not yet sufficient to replace traditional surveillance methods. Despite these limitations, continued search and validation of biomarkers is essential to improve risk prediction and early diagnosis. Combined panels that integrate genetic mutations, epigenetic alterations, and miRNA profiles may enable personalized surveillance strategies tailored to each patient’s molecular risk[88]. Validating these biomarkes in longitudinal UC cohorts is key to establishing their clinical utility and reducing both false negatives and unnecessary interventions. Finally, a deeper analysis of molecular profiles could transform UC surveillance by enabling earlier and more precise detection of patients at risk of development neoplasic disease.

THERAPEUTIC IMPLICATIONS IN UC AND CANCER PREVENTION

Treatment strategies in UC aim to achieve symptom remission, reduce inflammatory markers, prevent disability, and promote long-term endoscopic healing. Conventional therapy scheme includes 5-aminosalicylic acids (5-ASA), systemic corticosteroids, and immunomodulators. Treatment characteristics are described in Table 3. Although approximately 65% of newly diagnosed patients are managed with these strategies, the treatment of UC often requires additional monitoring of inflammation and adjustment of medical therapy to achieve clinical and endoscopic remission[89].

Table 3 Main drugs used in the treatment of ulcerative colitis: Doses, mechanisms of action, and therapeutic response.
Treatment
Dose scheme
Mechanism
Response
Ref.
5-ASAMesalazineInduction: 2.4-4.8 g/dayAnti-inflammatory by activating PPAR-y receptorsUC: Clinical and endoscopic remission[10,89,167,168]
Maintenance: 1.5-2.0 g/dayCD: Poor response
GlucocorticoidsBetamethasoneInduction: 5 mg/dayImmunosuppressors by reduced expression of IL-1, IL-1β and IL-8, TGF-β3 and IL-10UC: Clinical and endoscopic remission[167,169,170]
Budesonide MMXInduction and maintenance: 9 mg/day
HydrocortisoneInduction: 356 mg/dayCD: Clinical remission
PrednisoloneInduction: ≥ 30 mg/day
ThiopurinesAzathioprineInduction and maintenance: 1.5 to 2.5 mg/kg/dayImmunosupressor. Targets Rac1 activation and inhibits gut T cellsUC: Poor response in active disease. Used for remission maintenance[171-174]
CD: Clinical remission
6-mercaptopurineInduction and maintenance: 1-1.5 mg/kg/dayImmunosuppressor. Inhibits purine synthesisUC: Remission maintenance[175,176]
CD: Clinical remission or significant improvement
MethotrexateInduction and maintenance: 25 mg/weekImmunosupressor inhibits purine synthesisUC: Poor response[177-179]
Decrease in production of cytokines and eicosanoidsCD: Clinical remission and maintenance

Controlling inflammation is necessary to reduce complications such as colon cancer, strictures, fistulas, and abscesses, as well as to decrease the need for steroid regimens, hospitalizations, and surgical interventions. Usually, the treatment follows two phases: An induction and maintenance phase. The induction phase requires high doses of steroid-sparing medication for a few weeks to months to achieve remission[90]. Then, the maintenance phase requires lower doses of steroid-sparing medications, which may be combined with immunomodulators or biologic agents to maintain remission state and prevent relapses[89].

Patients with chronic UC commonly exhibit reduced expression of peroxisome proliferator-activated receptor-gamma (PPAR-γ) in their colonocytes. Therefore, new strategies involve 5-ASA analogs with greater PPAR-γ activity[10]. The combination of corticosteroids with rectal 5-ASA has also proven effectiveness in achieving clinical, endoscopic, and histologic remission[90]. Nevertheless, systemic steroids may be counterproductive, as they are associated with increased morbidity and mortality. They should only be used when no alternative agent is available for timely administration, and the excessive use of steroids is linked to a higher risk of complications, such as osteopenia and infections[89].

For glucocorticoid refractory patients, thiopurines or biological agents can be added to the treatment regimen. Immunomodulators include azathioprine, 6-mercaptopurine, and methotrexate[89,91]. Also, thiopurines such as azathioprine or 6-mercaptopurine may be effective for inducing remission in CD[10,91].

Colectomy remains the curative option for patients who are resistant to medical therapy, or those have intractable fulminant colitis, toxic megacolon, strictures, unresectable high-grade or multifocal dysplasia, cancer, or growth retardation in children[10]. Conventional therapies are usually associated with several side effects, such as nausea, headache, higher risk of infection, cytopenia, hepatitis, and agranulocytosis. Some of these treatments also modify the host gut microbiome, which contributes to increased IBD pathogenesis.

BIOLOGICS AGAINST TNF-Α, IL-12/23, INTEGRINS, JAK INHIBITORS

Biologic therapies target TNF-α, IL-12/23, integrins, and JAK signaling. These include anti-TNF agents such as infliximab, adalimumab, and golimumab; anti-IL-12/23 agents such as ustekinumab and risankizumab; anti-integrin therapy such as vedolizumab, which blocks the α4β7 integrin; and JAK inhibitors such as upadacitinib and tofacitinib. Biologic therapy is summarized in Table 4[10].

Table 4 Biologic strategies for inflammatory bowel disease.
Biologic effect
Treatment
Dose scheme
Mechanism
Response
Ref.
TNF-α inhibitorInfliximabInduction: Intravenously 5 mg/kg, 2 weeks and 6 weeksMonoclonal antibody against TNF-αClinical remission, reduced fistulous disease in UC[91,180,181]
Maintenance: Every 8 weeks thereafter
AdalimumabInduction: 160 mg followed by 80 mg after two weeksFully humanized IgG1 monoclonal antibody against TNF-αInduction and maintenance of remission in CD[91,182,183]
Maintenance: 40 mg every two weeksSome patients do not respond
UstekinumabInduction: 130 mg fixed dose or 6 mg/kg for 8-12 weeksIgG1 monoclonal antibody that binds to p40 subunit of pro-inflammatory IL 12 and 23Clinical remission in UC[90,91,180,184]
Maintenance: 90 mg every 8-12 weeks
RisankizumabInduction: 600 mg for12 weeks, or 1200 mg at 0 weeks, 4 weeks, and 8 weeksAntibody binds to p19 subunit of IL-23Improved clinical remission rate with short-term efficacy and safety in moderate-to-severe UC[91,185]
Maintenance: 180 mg or 360 mg every 8 weeks
Anti-adhesion molecule inhibitorsVedolizumabInduction: 300 mg at initial, 2 weeks and 6 weeksMonoclonal IgG1 antibody against α4-β7 integrin, and disruption of lymphocyte traffickingClinical and safety outcomes at 6-10 weeks in moderately to severe CD[91,186]
Maintenance: Same dose every 8 weeks
JAK inhibitorsUpadacitinibInduction: 45 mg/day for 12 weeksImmunosuppression by targeting JAK1Clinical remission and endoscopic response in CD[91,187,188]
Maintenance: 15-30 mg/day for 52 weeksImprovement of fecal calprotectin and C-reactive protein levels
TofacitinibInduction: 10 mg twice a day for 8 weeksInhibition of JAK1 and JAK3, JAK2 and TYK2, blocking signaling for IL-2, IL-4, IL-6, IL-7, IL-9, IL-15, IL-21, and IFN-γ cytokinesClinical response improvement and reduce of inflammatory markers in UC[90,91,189-191]
Maintenance: 5-10 mg twice a day for 26 weeks

Biologics offer several advantages, including improved surgical outcomes, higher rates of steroid-free remission, endoscopic healing, and reduced healthcare costs[92]. Combination therapy with anti-TNF agents and immunomodulators is particularly effective in moderate to severe IBD. For example, infliximab plus azathioprine achieves higher rates of steroid-free remission compared with monotherapy[89]. Moreover, combining anti-TNF agents with thiopurines enhances efficacy and reduces immunogenicity[91].

Emerging therapies: IL-17 inhibitors, gut microbiome modulators, cell therapy

Developing therapeutic approaches aim to modulate the inflammatory microenvironment through inhibitors of pro-inflammatory cytokines, gut microbiota enrichment, and cell-based therapies. A wide variety of immune cells and their related cytokines contribute to the pathogenicity of immune-mediated diseases, mainly by sustaining chronic inflammation. Although lesions from patients with IBD had revealed high IL-17 expression, blocking IL-17A is ineffective or may even worsen IBD and gastrointestinal events[93,94]. In contrast, monoclonal antibodies against IL23 p40 and p19 have demonstrated successful results in reducing intestinal inflammation[95].

Cytokine production ca also be reduced by lymphocyte downregulation. Retinoic acid receptor-related orphan receptor gamma t (RORγt) is the master transcriptional factor regulating expression of Th17 in T cells and group 3 innate-like cells[96]. Molecules targeting RORγt suppress TH17 differentiation and IL-17 production; therefore, they have been evaluated in several experimental autoimmune diseases and colitis models. RORγt is also a key regulator of the intestinal mucosal firewall, which provides a defensive barrier against microbial and dietary antigens through the mucus layer, epithelial cells, and the release of antimicrobial peptides and immunoglobulin A[97].

A study reported that the treatment of a RORγt inhibitor (BI119) in patients significantly reduced the transcription of inflammatory genes like IL17A, IL17F, and IL26 in colon and ileum. Additional downregulated genes in intestinal mucosa included IL23R, CSF2, CXCL1, CXCL8, IFNG, S100A8, IL6, IL10, and DEFA5[98]. Furthermore, in an immune-depleted mouse model of colitis induced by CD4+CD45RB high T cells, oral administration of BI119 reduced fecal lipocalin and circulating sCD14, followed reversing clinical and macroscopic signs of inflammation[98].

Modulation of the microbiome through probiotics and prebiotics has been well documented in several studies, demonstrating reductions in IBD symptoms and mucosal damage.

Probiotics could modulate the gut microbiota and, thereby, alter gene expression and signaling pathways responsible for maintaining immune homeostasis and epithelial integrity. Probiotic strains such as Escherichia coli Nissle 1917, Bifidobacteria, and Lactobacillus, modulate macrophage, dendritic cell, and T lymphocyte activity in IBD, UC, irritable bowel syndrome, and diverticulitis[99].

Cell therapy, including the use of hematopoietic stem cells, mesenchymal stem cells (MSCs), induced pluripotent stem cells, or modified T cells such as CAR-T cells, and Tregs, has also been explored for IBD treatment, showing promising results.

Stem cells possess regenerative and immunomodulatory properties that improve tissue healing in intestinal inflammatory diseases[100]. Although the mechanisms are not fully described, stem cells can be recruited to damaged tissues and followed differentiate into epithelial cells, regenerating mucosa or delivering anti-inflammatory cytokines[101].

Therapy with umbilical cord-derived MSCs in UC patients showed high clinical response and remission after 2 months of treatment, reducing inflammatory markers IL-1β, IL-8, IL-12, and IL-17, while increased hemoglobin, albumin, and IL-10/IL-17 ratio[102]. Adipose tissue-derived MSCs also improved IL-10 levels while inhibiting interferon-γ (IFN-γ) in peripheral blood mononuclear cells[103]. Another study showed that MSC can reduce the expression of pro-inflammatory cytokines (IL-1β and TNF), matrix metalloproteinases (MMP7, MMP10, MMP9 and MMP3), reactive oxygen species and nitrosylation genes (Nos2, S100a8 and S100a9), pathogen-sensing genes (Nod2 and Tlr2), and the antimicrobial gene Lcn2[104]. In vivo studies also showed lower disease activity index, reduced histopathological score, and increased colon length in mice treated with MSC[105].

Bone marrow-derived MSCs (BM-MSCs) exert immunosuppressive activity by regulating cytotoxic T cells and T regulatory cells. Clinical use of MSC is being evaluated in the phase II ADMIRE-CD trial (NCT01541579), which investigates the safety and efficacy of darvadstrocel for up to 104 weeks[103]. Another phase III multicenter, randomized, placebo-controlled trial of allogenic adipose-derived MSCs demonstrated statistically significant healing of perianal fistulas in CD patients[106].

Imbalance in the regulation of T cell populations is a key driver for IBD development. Typically, there is overactivation of Th1 and Th17 cells, which produce pro-inflammatory cytokines like IFN-γ, TNF-α, IL-17, and IL-22, promoting inflammation and tissue damage[107]. Commonly, in UC models, reduced levels of Tregs are frequently observed in peripheral blood, leading to uncontrolled inflammation and increased Th17 activity. Tregs are CD4+ T cells expressing the high affinity IL-2 receptor α-chain (CD25) and the master transcription factor FOXP3, which confers a suppressive phenotype that maintains immune homeostasis through the release of transforming growth factor β, IL-10, and IL-35[108,109].

Chimeric antigen receptor (CAR) therapy offers high specificity by targeting cells through antibody-derived variable region linked to signaling and costimulatory domains of immune receptors[110]. In turn, CAR-T cell therapies targeting IL-23 receptor for CD treatment have demonstrated CAR-dependent suppressive activity against Tregs, while providing protection in IBD mouse models[111]. Another study reported that IL-23-CAR Treg therapy reduced allogeneic CD4+ T-cell proliferation in a mixed leukocyte reaction. Importantly, IL-23-CAR Tregs maintain their regulatory phenotype while exerting antigen-specific immunosuppression and immunomodulation in CD[110], inhibiting dendritic cells maturation by their T-cell receptor or CAR signaling. A clinical study in China is currently evaluating CD7 CAR-T cells in UC (NCT05239702).

On the other hand, therapies using Tregs for IBD management have also been evaluated. Type I Treg cells are a subgroup characterized by IL-10 production and the absence of FOXP3 expression. In experimental colitis, mucosal type I Treg cells occupy a tolerogenic niche and suppress disease in vivo mouse models[111]. Furthermore, a highly specific retinoid acid receptor α agonist has been shown to induce integrin α4β7 expression on the Treg surface, enabling their homing to gut tissue in a humanized mouse model of colitis[108].

Treg cell transplantation in UC patients has improved stool frequency and rectal bleeding, promoted ulceration regression, reduced fecal calprotectin levels, and enhanced liver function[112]. Moreover, the combination of autologous Tregs with ovalbumin-specific T cells in patients with active CD resulted in dose-dependent improvements in clinical disease. Ex vivo expanded polyclonal Tregs have also been used in IBD clinical trials (NCT04691232; NCT03185000).

For UC, additional clinical studies are currently in progress, including a phase I, fast-track dose-escalation trial in patients with active disease receiving a single infusion of Treg cells. Another study using low-dose subcutaneous IL-2 therapy (Proleukin) to expand Treg in vivo demonstrated a reduction in UC severity in an open-label phase Ib/IIa induction trial[111].

PERSPECTIVE AND FUTURE DIRECTIONS

UC is a type of IBD characterized by an inflammatory pattern and ulceration of colon and rectum, leading to episodes of bloody diarrhea, abdominal pain, and a strong urge to defecate. The pathophysiology involves dysbiosis, disruption of the intestinal epithelial barrier, dysregulated immune response, and altered T-cell responses, as well as molecular pathways associated with chronic inflammation. However, the transition from UC to CRC is not a discrete event, but rather the consequence of a cascading series of alterations that progressively transform immunological tolerance into chronic destructive inflammation and, ultimately, into neoplastic transformation.

The dysbiosis observed in UC is characterized by depletion of bacteria producing short-chain fatty acids (Faecalibacterium prausnitzii, Roseburia spp., Ruminococcus spp.), which normally regulate barrier function and maintain immunological homeostasis. Concurrently, there is expansion of pro-inflammatory toxinogenic bacteria (adherent-invasive Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Bacteroides fragilis) that directly activate the innate TLR-NLRP3 axis. This dysbiotic state perpetuates not only local inflammation but also modulates specific metabolic pathways (amine and polyamine degradation) that have been directly associated with CRC development.

Activation of TLRs (TLR2 and TLR4) on dendritic cells within the lamina propria amplifies the production of pro-inflammatory cytokines (IL-6, IL-12, IL-23, TNF-α) that differentially activate Th cells. IL-12 participates in the differentiation of cells into the Th1 lineage, which has been reported to be associated with antitumor immunity, promoting the activation of cytotoxic T cells through the production of IFN-γ, TNF, and IL-2. IL-6 is a central mediator of the immune system and, in intestinal inflammation, promotes the survival of inflammatory cells and contributes to the disruption of the intestinal barrier[113]. Crucially, IL-23 promotes differentiation of Th17 cells, which produce IL-17 and IL-26 - cytokines that compromise epithelial barrier integrity and perpetuate leukocyte recruitment through CXCL8 and the mucosal addressin cell adhesion molecule-1. This crosstalk between innate and adaptive immunity creates an amplification circuit that resists natural resolution.

A key finding explaining UC chronicity is the multifaceted dysfunction of Tregs. Beyond numerical reduction, Tregs from UC patients exhibit multiple functional defects: (1) Compromised lineage stability with loss of FOXP3 expression; (2) Paradoxical activation of co-stimulatory markers (inducible T cell costimulator, programmed cell death protein 1, T cell immunoreceptor with Ig and ITIM domains) that reclassify them as pro-inflammatory hybrid cells (IL-17 + FOXP3+); and (3) Vulnerability to epigenetic destabilization mediated by IL-23. This loss of immunological tolerance is exacerbated by the local cytokine environment, which activates STAT3 and NF-κB, thereby blocking the IL-2/STAT5 axis critical for Treg maintenance.

Simultaneously, activated effector T cells display aberrant resistance to apoptosis mediated by survivin overexpression and altered BCL-2 family member expression. Abnormal lymphocyte activation further sustains tissue damage; survivin, an anti-apoptotic protein, is aberrantly expressed in UC immune cells, conferring resistance to apoptosis and contributing to CRC pathogenesis[114].

This apoptotic blockade converts lymphocytes that should be eliminated after antigen exposure into chronic producers of destructive cytokines (Th1/Th2/Th17). The result is a paradoxical accumulation of pro-inflammatory cells resistant to death alongside dysfunctional Tregs incapable of containing the response, generating a state of persistent “immunological anarchy”.

Alterations in T-cell subsets further highlight immune imbalance. A decrease in CD4+, CD25+, CD127- cells has been reported in patients with UC; this coincides with the findings of Qiu Junlan, who observed a significant increase in patients with gastrointestinal cancer compared to healthy controls[115]. Another depleted population is CD4+, CD25+, FOXP3- cells[43]; these cells participate in the tumor microenvironment by blocking the response of antitumor effector T cells[116]. Chronic inflammation generates a microenvironment rich in OS (elevated reactive oxygen species/reactive nitrogen species) that damages DNA. Sustained MAPK activation (particularly p38MAPK) in response to microbial toxins and pro-inflammatory cytokines amplifies this damage. At the epigenetic level, hyperactivation of NF-κB and STAT3 remodels the methylation landscape, silencing tumor suppressor genes. Recent evidence suggests that genes such as p53, KRAS, IDH1, and APC undergo genetic alterations more frequently in UC mucosa even before dysplasia development, indicating that the inflammatory microenvironment actively selects for cells with mutations "advantageous" for survival under chronic stress.

Molecular pathways such as STAT3 and NF-κB play predominant roles, mediating immune–tumor cell communication, regulating survival and apoptosis, and driving inflammation, proliferation, and angiogenesis. PI3K-AKT and mTOR regulate growth, metabolism, and survival, with disturbances in fatty acid synthesis, tryptophan metabolism, glycerophospholipid metabolism, and PPAR signaling linked to UC[117]. These findings have already been reviewed in the literature, demonstrating that PPAR-γ and PPAR-α influence the modulation of the functional phenotype of macrophages, T-cell differentiation, and epithelial barrier integrity, thereby influencing disease severity, progression, and potential complications, of CRC[118].

Interestingly, PPAR signaling, mTOR, and PI3K-AKT are just a few of the pathways mentioned above that share an upstream regulator AMPK. Beyond its established role in classical inflammatory pathways, exerts a dual and context-dependent regulatory function that bridges chronic mucosal inflammation and neoplastic transformation in UC. During the early inflammatory phase, AMPK behaves predominantly as a tumor-suppressive checkpoint: Its activation restrains NF-κB and MAPK signaling, limits NLRP3 inflammasome assembly and the resulting pyroptotic release of IL-1β and IL-18 and promotes protective autophagy that clears damaged mitochondria and misfolded proteins from stressed epithelial cells. Additionally, AMPK activation limits macrophage polarization toward the pro-inflammatory M1 phenotype and promotes the restoration of Th17/Treg equilibrium. This reduces the cytokine milieu (IL-6, IL-17, TNF-α) that supports genomic instability and DNA damage in the colonic mucosa. This protective role is not unqualified, though[72].

AMPK plays a complex and paradoxical role in cancer; the effects, depending on disease stage and biological context. AMPK activation is common observed in advanced cancers and may promote metabolic flexibility and improve antioxidant defenses, which can promote resistance therapeutic as chemotherapy and radiotherapy[119]. In vivo models of CRC, AMPK activation can suppress tumor growth by inhibit mTORC1 which produce reduce lipid synthesis, cell cycle arrest and autophagy during conditions as nutrient deprivation, hypoxia or OS[120]. The balance between dual effects depends from factors like liver kinase B1/serine/threonine kinase 11, levels of oxygen and nutrients available and interactions with others pathways such as PI3K-AKT, NF-κB and MAPK[121]. Neither of AMPK effects in UC-CRC can be addressed simplistically; rather, a disease-stage-specific strategy is required that leverages AMPK anti-inflammatory and mucosal barrier-protective properties during active inflammation, while remaining mindful of its potential to promote malignant transformation[122].

This article allows us to integrate the multiple mechanisms involved in UC and to view treatment as a relevant strategy for preventing or delaying the onset of UC, although it has been reported that the one-year clinical remission rate is only about 40%[123]. It is important to approach treatment holistically, as lifestyle plays a decisive role in triggering mechanisms; therefore, the goal is to avoid trigger foods during active phases of the disease, suggesting limiting dairy products, highly seasoned foods, fats, insoluble fiber, and caffeine - all to prevent, according to the published literature, triggering changes in the microbiota and the bacteriophage population, as these can influence mucosal immune responses - either directly or indirectly - leading to dysregulation characterized by increased production of pro-inflammatory cytokines, such as IL-1β, IL-6, TNF-α, and cytokines associated with Th1, Th2, and Th17 cells[124].

Drug treatment varies depending on the severity of the disease. Currently, mesalazine or sulfasalazine are used as first-line treatments for mild to moderate cases, while corticosteroids such as prednisone or budesonide - potent anti-inflammatory drugs - are used for short-term management during severe flare-ups. However, osteoporosis and weight gain are unwanted side effects that can complicate UC. Immunomodulators such as azathioprine or mercaptopurine, which modify the immune system, and biologic therapies and small molecules that block specific immune system proteins causing inflammation - such as adalimumab, infliximab, ustekinumab, or vedolizumab - are indicated when other medications fail to control the disease. Currently, given the need to prevent progression to CRC and to explore whether treatment could serve as a preventive strategy, exosomes derived from MSCs have been proposed, demonstrating a protective role against UC and CRC. Exosomes from human UC-MSCs, human BM-MSCs, AD-MSCs, and olfactory ecto-MSCs improve experimental UC by suppressing inflammatory cells, and exosomes from human BM-MSCs and human UC-MSCs containing miR-3940-5p/miR-22-3p/miR-16-5p inhibit the proliferation, migration, and invasion of CRC cells by regulating the RAP2B/PI3K/AKT and integrin subunit alpha 2/integrin subunit alpha 6 signaling pathways, demonstrating a promising role[125].

CONCLUSION

The findings from the reviewed evidence suggest that the interaction between genetic, environmental, microbial, and immunological factors disrupts the regulation of molecular pathways such as AKT, JAK-STAT, and NF-κB. Furthermore, the disruption of intestinal homeostasis, the activation of innate and adaptive immune cells, and the production of proinflammatory cytokines contribute to sustained damage to the intestinal mucosa. These alterations not only contribute to the chronicity of UC but also create conditions conducive to the development of CRC, such as the accumulation of molecular damage, OS, and genomic instability.

Understanding the molecular and cellular mechanisms involved in UC and CRC offers opportunities for the establishment of early biosignatures and the development of targeted therapeutic strategies that can reduce disease progression and the risk of malignant transformation. Therefore, future research should delve deeper into the immuno-inflammatory processes that link these two conditions.

Based on this integrative framework, we propose some priority for future research: (1) The identification and validation of early diagnostic biomarkers continue be critical. Molecular signatures derived from dysregulated Treg cell function (FOXP3 stability, IL-17 + FOXP3+ hybrid phenotypes), persistent NF-κB, STAT3 activation, or circulating markers of genomic instability (p53, KRAS, APC alterations) could enable earlier detection of the transition from inflammation to neoplasia, before overt dysplasia becomes histologically evident; (2) The development of precision therapies tailored to disease stage and molecular context. Rather than uniform inhibition of signaling the dual pathways, strategies should be adjusted to each patients inflammatory and metabolic profile, guided by biomarkers that distinguish predominantly inflammation phenotypes from those already showing early neoplastic characteristics; and (3) The dual effect of AMPK depends on behavior such as inflammation promoting tumor survival once neoplastic transformation. Future studies should elucidate the molecular switches driving this functional shift to guide AMPK modulation and prevent risk of UC-CRC.

ACKNOWLEDGEMENTS

We dedicate this work to our colleague Verónica Lisset Loaiza Gutiérrez and to all those living with diagnosis of Inflammatory Bowel Disease, in recognition of their strength and perseverance in the process of facing this disease. May this work contribute, from a scientific perspective to the generation of useful knowledge to improve their health care and quality of life.

References
1.  Feuerstein JD, Moss AC, Farraye FA. Ulcerative Colitis. Mayo Clin Proc. 2019;94:1357-1373.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 361]  [Cited by in RCA: 330]  [Article Influence: 47.1]  [Reference Citation Analysis (1)]
2.  Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, Ziade N, Hashash JG. A comprehensive review and update on ulcerative colitis(). Dis Mon. 2019;65:100851.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 492]  [Cited by in RCA: 429]  [Article Influence: 61.3]  [Reference Citation Analysis (9)]
3.  Sun Y, Zhang Z, Zheng CQ, Sang LX. Mucosal lesions of the upper gastrointestinal tract in patients with ulcerative colitis: A review. World J Gastroenterol. 2021;27:2963-2978.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in CrossRef: 80]  [Cited by in RCA: 71]  [Article Influence: 14.2]  [Reference Citation Analysis (1)]
4.  Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-535.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 2395]  [Cited by in RCA: 2143]  [Article Influence: 85.7]  [Reference Citation Analysis (14)]
5.  Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012;10:639-645.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 784]  [Cited by in RCA: 721]  [Article Influence: 51.5]  [Reference Citation Analysis (6)]
6.  Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, Oldenburg B. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis. 2013;19:789-799.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 461]  [Cited by in RCA: 422]  [Article Influence: 32.5]  [Reference Citation Analysis (6)]
7.  Castaño-Milla C, Chaparro M, Gisbert JP. Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther. 2014;39:645-659.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 228]  [Cited by in RCA: 215]  [Article Influence: 17.9]  [Reference Citation Analysis (4)]
8.  Terry R, Chintanaboina J, Patel D, Lippert B, Haner M, Price K, Tracy A, Lalos A, Wakeley M, Gutierrez LS. Expression of WIF-1 in inflammatory bowel disease. Histol Histopathol. 2019;34:149-157.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 3]  [Reference Citation Analysis (0)]
9.  Vancamelbeke M, Vermeire S. The intestinal barrier: a fundamental role in health and disease. Expert Rev Gastroenterol Hepatol. 2017;11:821-834.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 1102]  [Cited by in RCA: 999]  [Article Influence: 111.0]  [Reference Citation Analysis (6)]
10.  Lynch WD, Hsu R.   Ulcerative Colitis. 2023 Jun 5. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-.  [PubMed]  [DOI]
11.  Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, Hibi T. Ulcerative colitis. Nat Rev Dis Primers. 2020;6:74.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1386]  [Cited by in RCA: 1327]  [Article Influence: 221.2]  [Reference Citation Analysis (7)]
12.  de Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13:13-27.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1339]  [Cited by in RCA: 1238]  [Article Influence: 123.8]  [Reference Citation Analysis (11)]
13.  Corridoni D, Antanaviciute A, Gupta T, Fawkner-Corbett D, Aulicino A, Jagielowicz M, Parikh K, Repapi E, Taylor S, Ishikawa D, Hatano R, Yamada T, Xin W, Slawinski H, Bowden R, Napolitani G, Brain O, Morimoto C, Koohy H, Simmons A. Single-cell atlas of colonic CD8(+) T cells in ulcerative colitis. Nat Med. 2020;26:1480-1490.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 210]  [Cited by in RCA: 192]  [Article Influence: 32.0]  [Reference Citation Analysis (3)]
14.  Sun L, Kong R, Li H, Wang D. The Role of T Follicular Helper Cells and Interleukin-21 in the Pathogenesis of Inflammatory Bowel Disease. Gastroenterol Res Pract. 2021;2021:9621738.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 2]  [Cited by in RCA: 13]  [Article Influence: 2.6]  [Reference Citation Analysis (1)]
15.  Boland BS, He Z, Tsai MS, Olvera JG, Omilusik KD, Duong HG, Kim ES, Limary AE, Jin W, Milner JJ, Yu B, Patel SA, Louis TL, Tysl T, Kurd NS, Bortnick A, Quezada LK, Kanbar JN, Miralles A, Huylebroeck D, Valasek MA, Dulai PS, Singh S, Lu LF, Bui JD, Murre C, Sandborn WJ, Goldrath AW, Yeo GW, Chang JT. Heterogeneity and clonal relationships of adaptive immune cells in ulcerative colitis revealed by single-cell analyses. Sci Immunol. 2020;5:eabb4432.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 247]  [Cited by in RCA: 229]  [Article Influence: 38.2]  [Reference Citation Analysis (4)]
16.  Souza RF, Caetano MAF, Magalhães HIR, Castelucci P. Study of tumor necrosis factor receptor in the inflammatory bowel disease. World J Gastroenterol. 2023;29:2733-2746.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in CrossRef: 143]  [Cited by in RCA: 117]  [Article Influence: 39.0]  [Reference Citation Analysis (1)]
17.  He R, Zhao S, Cui M, Chen Y, Ma J, Li J, Wang X. Cutaneous manifestations of inflammatory bowel disease: basic characteristics, therapy, and potential pathophysiological associations. Front Immunol. 2023;14:1234535.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 29]  [Reference Citation Analysis (0)]
18.  Zhu Y, Yang S, Zhao N, Liu C, Zhang F, Guo Y, Liu H. CXCL8 chemokine in ulcerative colitis. Biomed Pharmacother. 2021;138:111427.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 82]  [Cited by in RCA: 82]  [Article Influence: 16.4]  [Reference Citation Analysis (0)]
19.  Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14:329-342.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 2350]  [Cited by in RCA: 2173]  [Article Influence: 181.1]  [Reference Citation Analysis (9)]
20.  Takahashi K, Nishida A, Fujimoto T, Fujii M, Shioya M, Imaeda H, Inatomi O, Bamba S, Sugimoto M, Andoh A. Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn's Disease. Digestion. 2016;93:59-65.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 521]  [Cited by in RCA: 474]  [Article Influence: 47.4]  [Reference Citation Analysis (9)]
21.  Palmela C, Chevarin C, Xu Z, Torres J, Sevrin G, Hirten R, Barnich N, Ng SC, Colombel JF. Adherent-invasive Escherichia coli in inflammatory bowel disease. Gut. 2018;67:574-587.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 476]  [Cited by in RCA: 436]  [Article Influence: 54.5]  [Reference Citation Analysis (7)]
22.  Zhang J, Hoedt EC, Liu Q, Berendsen E, Teh JJ, Hamilton A, O' Brien AW, Ching JYL, Wei H, Yang K, Xu Z, Wong SH, Mak JWY, Sung JJY, Morrison M, Yu J, Kamm MA, Ng SC. Elucidation of Proteus mirabilis as a Key Bacterium in Crohn's Disease Inflammation. Gastroenterology. 2021;160:317-330.e11.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 90]  [Cited by in RCA: 107]  [Article Influence: 21.4]  [Reference Citation Analysis (1)]
23.  Zhang Q, Su X, Zhang C, Chen W, Wang Y, Yang X, Liu D, Zhang Y, Yang R. Klebsiella pneumoniae Induces Inflammatory Bowel Disease Through Caspase-11-Mediated IL18 in the Gut Epithelial Cells. Cell Mol Gastroenterol Hepatol. 2023;15:613-632.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 1]  [Cited by in RCA: 52]  [Article Influence: 17.3]  [Reference Citation Analysis (1)]
24.  Espinosa JR, Wheaton JD, Ciofani M. In Vitro Differentiation of CD4(+) T Cell Effector and Regulatory Subsets. Methods Mol Biol. 2020;2111:79-89.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1]  [Cited by in RCA: 9]  [Article Influence: 1.5]  [Reference Citation Analysis (0)]
25.  Zhou YT, Zhang QG, Du SY, Chen H, Zhu MZ, Ai M, Li SS, Dai MN, Wang XT, Jin Y, Zhu YW, Lu J, Xu F, Zhu XX, Qiu LY, Sun HJ. Atg7 in CD4(+) T cells improves intestinal mucosal inflammation by regulating Ets1-mediated T cell differentiation. Clin Transl Med. 2025;15:e70462.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 4]  [Cited by in RCA: 4]  [Article Influence: 4.0]  [Reference Citation Analysis (0)]
26.  Liang Y, Li Y, Lee C, Yu Z, Chen C, Liang C. Ulcerative colitis: molecular insights and intervention therapy. Mol Biomed. 2024;5:42.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 100]  [Cited by in RCA: 118]  [Article Influence: 59.0]  [Reference Citation Analysis (0)]
27.  Lechner K, Mott S, Al-Saifi R, Knipfer L, Wirtz S, Atreya R, Vieth M, Rath T, Fraass T, Winter Z, August A, Luban J, Zimmermann VS, Weigmann B, Neurath MF. Targeting of the Tec Kinase ITK Drives Resolution of T Cell-Mediated Colitis and Emerges as Potential Therapeutic Option in Ulcerative Colitis. Gastroenterology. 2021;161:1270-1287.e19.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 13]  [Cited by in RCA: 21]  [Article Influence: 4.2]  [Reference Citation Analysis (0)]
28.  Jaiswal PK, Goel A, Mittal RD. Survivin: A molecular biomarker in cancer. Indian J Med Res. 2015;141:389-397.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 282]  [Cited by in RCA: 256]  [Article Influence: 23.3]  [Reference Citation Analysis (0)]
29.  Feng BS, Ma N, Zhang YY, Gao H, Zhang C, Li G, Liu Z, Feng Y, Yu HQ, Xiao L, Liu ZG, Yang PC. Survivin Impairs the Apoptotic Machinery in CD4+ T Cells of Patients with Ulcerative Colitis. J Innate Immun. 2020;12:226-234.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 9]  [Cited by in RCA: 11]  [Article Influence: 1.6]  [Reference Citation Analysis (0)]
30.  Pizarro TT, Stappenbeck TS, Rieder F, Rosen MJ, Colombel JF, Donowitz M, Towne J, Mazmanian SK, Faith JJ, Hodin RA, Garrett WS, Fichera A, Poritz LS, Cortes CJ, Shtraizent N, Honig G, Snapper SB, Hurtado-Lorenzo A, Salzman NH, Chang EB. Challenges in IBD Research: Preclinical Human IBD Mechanisms. Inflamm Bowel Dis. 2019;25:S5-S12.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 71]  [Cited by in RCA: 69]  [Article Influence: 9.9]  [Reference Citation Analysis (1)]
31.  Ina K, Itoh J, Fukushima K, Kusugami K, Yamaguchi T, Kyokane K, Imada A, Binion DG, Musso A, West GA, Dobrea GM, McCormick TS, Lapetina EG, Levine AD, Ottaway CA, Fiocchi C. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol. 1999;163:1081-1090.  [PubMed]  [DOI]
32.  Jin S, Mutvei AP, Chivukula IV, Andersson ER, Ramsköld D, Sandberg R, Lee KL, Kronqvist P, Mamaeva V, Ostling P, Mpindi JP, Kallioniemi O, Screpanti I, Poellinger L, Sahlgren C, Lendahl U. Non-canonical Notch signaling activates IL-6/JAK/STAT signaling in breast tumor cells and is controlled by p53 and IKKα/IKKβ. Oncogene. 2013;32:4892-4902.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 95]  [Cited by in RCA: 122]  [Article Influence: 8.7]  [Reference Citation Analysis (2)]
33.  He H, Chen Q, Fan H, Leng XY, Zhu F, Gao F, Zhou Q, Dong Y, Yang J. Extracellular vesicles produced by bone marrow mesenchymal stem cells overexpressing programmed death-ligand 1 ameliorate dextran sodium sulfate-induced ulcerative colitis in rats by regulating Th17/Treg cell balance through PTEN/PI3K/AKT/mTOR axis. J Gastroenterol Hepatol. 2022;37:2243-2254.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 24]  [Reference Citation Analysis (0)]
34.  Huang X, Lin R, Liu H, Dai M, Guo J, Hui W, Liu W, Haerken M, Zheng R, Yushanjiang T, Gao F. Resatorvid (TAK-242) Ameliorates Ulcerative Colitis by Modulating Macrophage Polarization and T Helper Cell Balance via TLR4/JAK2/STAT3 Signaling Pathway. Inflammation. 2024;47:2108-2128.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 16]  [Reference Citation Analysis (0)]
35.  Monteleone I, Pallone F, Monteleone G. Th17-related cytokines: new players in the control of chronic intestinal inflammation. BMC Med. 2011;9:122.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 73]  [Cited by in RCA: 75]  [Article Influence: 5.0]  [Reference Citation Analysis (0)]
36.  Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007;117:514-521.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1081]  [Cited by in RCA: 1018]  [Article Influence: 53.6]  [Reference Citation Analysis (4)]
37.  Strober W, Zhang F, Kitani A, Fuss I, Fichtner-Feigl S. Proinflammatory cytokines underlying the inflammation of Crohn's disease. Curr Opin Gastroenterol. 2010;26:310-317.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 90]  [Cited by in RCA: 80]  [Article Influence: 5.0]  [Reference Citation Analysis (2)]
38.  Krishnan K, Arnone B, Buchman A. Intestinal growth factors: potential use in the treatment of inflammatory bowel disease and their role in mucosal healing. Inflamm Bowel Dis. 2011;17:410-422.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 74]  [Cited by in RCA: 92]  [Article Influence: 6.1]  [Reference Citation Analysis (0)]
39.  Mudter J, Neurath MF. Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications. Gut. 2007;56:293-303.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 99]  [Cited by in RCA: 99]  [Article Influence: 5.2]  [Reference Citation Analysis (0)]
40.  Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol. 2007;8:1353-1362.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 971]  [Cited by in RCA: 930]  [Article Influence: 48.9]  [Reference Citation Analysis (1)]
41.  Guidi L, Felice C, Procoli A, Bonanno G, Martinelli E, Marzo M, Mocci G, Pugliese D, Andrisani G, Danese S, De Vitis I, Papa A, Armuzzi A, Rutella S. FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents. Biomed Res Int. 2013;2013:286368.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 23]  [Cited by in RCA: 27]  [Article Influence: 2.1]  [Reference Citation Analysis (0)]
42.  Duan S, Cao Y, Chen P, Yang Y, Zhang Y. Circulating and intestinal regulatory T cells in inflammatory bowel disease: A systemic review and meta-analysis. Int Rev Immunol. 2024;43:83-94.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 3]  [Cited by in RCA: 9]  [Article Influence: 3.0]  [Reference Citation Analysis (0)]
43.  Jalalvand M, Enayati S, Akhtari M, Madreseh E, Jamshidi A, Farhadi E, Mahmoudi M, Amirzargar A. Blood regulatory T cells in inflammatory bowel disease, a systematic review, and meta-analysis. Int Immunopharmacol. 2023;117:109824.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 14]  [Reference Citation Analysis (0)]
44.  Long Y, Xia C, Zheng X, Feng J, Li W, Ma Y, Sun Y, Zeng X, Liu C. Functional alterations in colonic CD4+T and regulatory T cells drive immune imbalance in ulcerative colitis. Immunol Lett. 2025;275:107010.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 3]  [Reference Citation Analysis (0)]
45.  Lee C, Park YW, Park MH, Lee YJ, Rhee I. Regulatory T cells and their role in inflammatory bowel disease: molecular targets, therapeutic strategies and translational advances. Biochem Pharmacol. 2025;239:117087.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 9]  [Cited by in RCA: 16]  [Article Influence: 16.0]  [Reference Citation Analysis (0)]
46.  Khan MJ, Lee YJ, Lee SY, Chung H, Nguyen-Phuong T, Kim YH, Park CG, Kang YM. Novel Autologous Regulatory T-Cell Therapy Ameliorates DSS-Induced Colitis in Humanized Mice. Inflamm Bowel Dis. 2025;31:2535-2546.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 7]  [Cited by in RCA: 6]  [Article Influence: 6.0]  [Reference Citation Analysis (0)]
47.  Gong Y, Lin Y, Zhao N, He X, Lu A, Wei W, Jiang M. The Th17/Treg Immune Imbalance in Ulcerative Colitis Disease in a Chinese Han Population. Mediators Inflamm. 2016;2016:7089137.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 25]  [Cited by in RCA: 56]  [Article Influence: 5.6]  [Reference Citation Analysis (1)]
48.  Jung MK, Kwak JE, Shin EC. IL-17A-Producing Foxp3(+) Regulatory T Cells and Human Diseases. Immune Netw. 2017;17:276-286.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 78]  [Cited by in RCA: 91]  [Article Influence: 10.1]  [Reference Citation Analysis (2)]
49.  Kibriya MG, Jasmine F, Pekow J, Munoz A, Weber C, Raza M, Kamal M, Ahsan H, Bissonnette M. Pathways Related to Colon Inflammation Are Associated with Colorectal Carcinoma: A Transcriptome- and Methylome-Wide Study. Cancers (Basel). 2023;15:2921.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 8]  [Reference Citation Analysis (2)]
50.  Shahgoli VK, Noorolyai S, Ahmadpour Youshanlui M, Saeidi H, Nasiri H, Mansoori B, Holmskov U, Baradaran B. Inflammatory bowel disease, colitis, and cancer: unmasking the chronic inflammation link. Int J Colorectal Dis. 2024;39:173.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 1]  [Cited by in RCA: 45]  [Article Influence: 22.5]  [Reference Citation Analysis (2)]
51.  Rachma B, Pamungkas RP, Sandra DY, Sutanto H, Fetarayani D. The immunological nexus between inflammatory bowel disease and colorectal cancer: A molecular perspective. Clinical Immunology Communications. 2025;8:138-158.  [PubMed]  [DOI]  [Full Text]
52.  Hanlon MM, Rakovich T, Cunningham CC, Ansboro S, Veale DJ, Fearon U, McGarry T. STAT3 Mediates the Differential Effects of Oncostatin M and TNFα on RA Synovial Fibroblast and Endothelial Cell Function. Front Immunol. 2019;10:2056.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 27]  [Cited by in RCA: 85]  [Article Influence: 12.1]  [Reference Citation Analysis (0)]
53.  Wang Z, Chang Y, Sun H, Li Y, Tang T. Advances in molecular mechanisms of inflammatory bowel diseaseassociated colorectal cancer (Review). Oncol Lett. 2024;27:257.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 21]  [Cited by in RCA: 24]  [Article Influence: 12.0]  [Reference Citation Analysis (1)]
54.  Han J, Theiss AL. Stat3: friend or foe in colitis and colitis-associated cancer? Inflamm Bowel Dis. 2014;20:2405-2411.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 29]  [Cited by in RCA: 45]  [Article Influence: 3.8]  [Reference Citation Analysis (0)]
55.  Gargalionis AN, Papavassiliou KA, Papavassiliou AG. Targeting STAT3 Signaling Pathway in Colorectal Cancer. Biomedicines. 2021;9:1016.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 61]  [Cited by in RCA: 83]  [Article Influence: 16.6]  [Reference Citation Analysis (5)]
56.  Fan Y, Mao R, Yang J. NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell. 2013;4:176-185.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 654]  [Cited by in RCA: 639]  [Article Influence: 49.2]  [Reference Citation Analysis (2)]
57.  Sadati S, Khalaji A, Bonyad A, Khoshdooz S, Hosseini Kolbadi KS, Bahrami A, Moeinfar MS, Morshedi M, Ghamsaraian A, Eterafi M, Eshraghi R, Khaksary Mahabady M, Mirzaei H. NF-κB and apoptosis: colorectal cancer progression and novel strategies for treatment. Eur J Med Res. 2025;30:616.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 27]  [Cited by in RCA: 27]  [Article Influence: 27.0]  [Reference Citation Analysis (0)]
58.  Zou S, Tong Q, Liu B, Huang W, Tian Y, Fu X. Targeting STAT3 in Cancer Immunotherapy. Mol Cancer. 2020;19:145.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 909]  [Cited by in RCA: 879]  [Article Influence: 146.5]  [Reference Citation Analysis (11)]
59.  Pacifico T, Stolfi C, Tomassini L, Luiz-Ferreira A, Franzè E, Ortenzi A, Colantoni A, Sica GS, Sambucci M, Monteleone I, Monteleone G, Laudisi F. Rafoxanide negatively modulates STAT3 and NF-κB activity and inflammation-associated colon tumorigenesis. Cancer Sci. 2024;115:3596-3611.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 6]  [Reference Citation Analysis (0)]
60.  Moafian Z, Maghrouni A, Soltani A, Hashemy SI. Cross-talk between non-coding RNAs and PI3K/AKT/mTOR pathway in colorectal cancer. Mol Biol Rep. 2021;48:4797-4811.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 5]  [Cited by in RCA: 28]  [Article Influence: 5.6]  [Reference Citation Analysis (1)]
61.  Bhat AA, Uppada S, Achkar IW, Hashem S, Yadav SK, Shanmugakonar M, Al-Naemi HA, Haris M, Uddin S. Tight Junction Proteins and Signaling Pathways in Cancer and Inflammation: A Functional Crosstalk. Front Physiol. 2018;9:1942.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 334]  [Cited by in RCA: 309]  [Article Influence: 44.1]  [Reference Citation Analysis (2)]
62.  Winkelmann P, Unterweger AL, Khullar D, Beigel F, Koletzko L, Siebeck M, Gropp R. The PI3K pathway as a therapeutic intervention point in inflammatory bowel disease. Immun Inflamm Dis. 2021;9:804-818.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 26]  [Cited by in RCA: 24]  [Article Influence: 4.8]  [Reference Citation Analysis (0)]
63.  Niu S, Zhang Y. Targeting the PI3K/Akt pathway for the treatment of ulcerative colitis: integrative regulatory features of traditional Chinese medicine. Front Pharmacol. 2025;16:1620138.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 9]  [Reference Citation Analysis (0)]
64.  Mayer IA, Arteaga CL. The PI3K/AKT Pathway as a Target for Cancer Treatment. Annu Rev Med. 2016;67:11-28.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 466]  [Cited by in RCA: 661]  [Article Influence: 60.1]  [Reference Citation Analysis (7)]
65.  Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol. 2018;15:273-291.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 889]  [Cited by in RCA: 834]  [Article Influence: 104.3]  [Reference Citation Analysis (3)]
66.  Leiphrakpam PD, Chowdhury S, Wang J, Black JD, Are C. The role and therapeutic implications of PI3K signaling pathway in cancer. J Surg Oncol. 2021;123:39-41.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 16]  [Cited by in RCA: 14]  [Article Influence: 2.8]  [Reference Citation Analysis (0)]
67.  Egwuagu CE. STAT3 in CD4+ T helper cell differentiation and inflammatory diseases. Cytokine. 2009;47:149-156.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 169]  [Cited by in RCA: 188]  [Article Influence: 11.1]  [Reference Citation Analysis (1)]
68.  Seif F, Khoshmirsafa M, Aazami H, Mohsenzadegan M, Sedighi G, Bahar M. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal. 2017;15:23.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 686]  [Cited by in RCA: 592]  [Article Influence: 65.8]  [Reference Citation Analysis (1)]
69.  Croker BA, Kiu H, Nicholson SE. SOCS regulation of the JAK/STAT signalling pathway. Semin Cell Dev Biol. 2008;19:414-422.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 491]  [Cited by in RCA: 488]  [Article Influence: 27.1]  [Reference Citation Analysis (4)]
70.  Long D, Mao C, Zhang W, Zhu Y, Xu Y. Natural products for the treatment of ulcerative colitis: focus on the JAK/STAT pathway. Front Immunol. 2025;16:1538302.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 1]  [Cited by in RCA: 26]  [Article Influence: 26.0]  [Reference Citation Analysis (0)]
71.  Lin H, Honglang L, Weifeng L, Junmin C, Jiantao Y, Junjing G. The mechanism of alopolysaccharide protecting ulceralive colitis. Biomed Pharmacother. 2017;88:145-150.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 16]  [Cited by in RCA: 35]  [Article Influence: 3.9]  [Reference Citation Analysis (0)]
72.  Yuan Y, Wang F, Liu X, Shuai B, Fan H. The Role of AMPK Signaling in Ulcerative Colitis. Drug Des Devel Ther. 2023;17:3855-3875.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 31]  [Reference Citation Analysis (0)]
73.  Yan Y, Mukherjee S, Harikumar KG, Strutzenberg TS, Zhou XE, Suino-Powell K, Xu TH, Sheldon RD, Lamp J, Brunzelle JS, Radziwon K, Ellis A, Novick SJ, Vega IE, Jones RG, Miller LJ, Xu HE, Griffin PR, Kossiakoff AA, Melcher K. Structure of an AMPK complex in an inactive, ATP-bound state. Science. 2021;373:413-419.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 54]  [Cited by in RCA: 91]  [Article Influence: 18.2]  [Reference Citation Analysis (0)]
74.  Jeon SM, Chandel NS, Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature. 2012;485:661-665.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 1004]  [Cited by in RCA: 966]  [Article Influence: 69.0]  [Reference Citation Analysis (7)]
75.  Xu Y, Bai L, Yang X, Huang J, Wang J, Wu X, Shi J. Recent advances in anti-inflammation via AMPK activation. Heliyon. 2024;10:e33670.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 38]  [Reference Citation Analysis (0)]
76.  Larabi A, Barnich N, Nguyen HTT. New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD. Autophagy. 2020;16:38-51.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 719]  [Cited by in RCA: 670]  [Article Influence: 111.7]  [Reference Citation Analysis (6)]
77.  Foerster EG, Mukherjee T, Cabral-Fernandes L, Rocha JDB, Girardin SE, Philpott DJ. How autophagy controls the intestinal epithelial barrier. Autophagy. 2022;18:86-103.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 338]  [Cited by in RCA: 339]  [Article Influence: 84.8]  [Reference Citation Analysis (2)]
78.  Dërmaku-Sopjani M, Morina R, Sermaxhaj F, Kurti F, Latifi J, Sopjani M. AMPK signaling in cancer: dual roles, molecular mechanisms, and therapeutic potential. Adv Med Sci. 2026;71:196-211.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 2]  [Reference Citation Analysis (0)]
79.  Jia J, Liu Y, Wang D, Pan Z, Zheng Q, Lu J, Liang C, Li D. Ulcerative colitis: signaling pathways, therapeutic targets and interventional strategies. Signal Transduct Target Ther. 2026;11:51.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 8]  [Cited by in RCA: 27]  [Article Influence: 27.0]  [Reference Citation Analysis (0)]
80.  Yan S, Wei H, Jia R, Zhen M, Bao S, Wang W, Liu F, Li J. Wu-Mei-Wan Ameliorates Murine Ulcerative Colitis by Regulating Macrophage Polarization. Front Pharmacol. 2022;13:859167.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 2]  [Cited by in RCA: 24]  [Article Influence: 6.0]  [Reference Citation Analysis (0)]
81.  Li C, Li Z, Zheng Y. Natural products targeting the MAPK signaling pathway: potential options for ulcerative colitis treatment. Front Pharmacol. 2025;16:1721584.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 4]  [Reference Citation Analysis (0)]
82.  Koveitypour Z, Panahi F, Vakilian M, Peymani M, Seyed Forootan F, Nasr Esfahani MH, Ghaedi K. Signaling pathways involved in colorectal cancer progression. Cell Biosci. 2019;9:97.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 345]  [Cited by in RCA: 305]  [Article Influence: 43.6]  [Reference Citation Analysis (6)]
83.  Zhang Y, Zuo A, Ba Y, Liu S, Chen J, Yang S, Weng S, Chen Y, Xu H, Luo P, Cheng Q, Tang B, Liu B, Zhang C, Yang J, Han X, Liu Z. Cancer-associated fibroblast-derived SEMA3C facilitates colorectal cancer liver metastasis via NRP2-mediated MAPK activation. Proc Natl Acad Sci U S A. 2025;122:e2423077122.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 3]  [Cited by in RCA: 17]  [Article Influence: 17.0]  [Reference Citation Analysis (0)]
84.  Xu Y, Ou J, Zhang C, Chen J, Chen J, Li A, Huang B, Zhao X. Rapamycin promotes the intestinal barrier repair in ulcerative colitis via the mTOR/PBLD/AMOT signaling pathway. Biochim Biophys Acta Mol Basis Dis. 2024;1870:167287.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 19]  [Reference Citation Analysis (0)]
85.  Kaur H, Moreau R. Role of mTORC1 in intestinal epithelial repair and tumorigenesis. Cell Mol Life Sci. 2019;76:2525-2546.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 23]  [Cited by in RCA: 35]  [Article Influence: 5.0]  [Reference Citation Analysis (0)]
86.  Shahnazari M, Afshar S, Emami MH, Amini R, Jalali A. Novel biomarkers for neoplastic progression from ulcerative colitis to colorectal cancer: a systems biology approach. Sci Rep. 2023;13:3413.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 14]  [Reference Citation Analysis (0)]
87.  Chen R, Lai LA, Brentnall TA, Pan S. Biomarkers for colitis-associated colorectal cancer. World J Gastroenterol. 2016;22:7882-7891.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in CrossRef: 22]  [Cited by in RCA: 35]  [Article Influence: 3.5]  [Reference Citation Analysis (0)]
88.  Kritzinger J, Kotrri G, Lakatos PL, Bessissow T, Wild G. The Role of Biomarkers in Surveillance of Ulcerative Colitis-Associated Colorectal Cancer: A Scoping Review. J Clin Med. 2025;14:5979.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 4]  [Reference Citation Analysis (0)]
89.  Cushing K, Higgins PDR. Management of Crohn Disease: A Review. JAMA. 2021;325:69-80.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 291]  [Cited by in RCA: 282]  [Article Influence: 56.4]  [Reference Citation Analysis (7)]
90.  Fuxman C, Sicilia B, Linares ME, García-López S, González Sueyro R, González-Lamac Y, Zabana Y, Hinojosa J, Barreiro-de Acosta M, Balderramo D, Balfour D, Bellicoso M, Daffra P, Morelli D, Orsi M, Rausch A, Ruffinengo O, Toro M, Sambuelli A, Novillo A, Gomollón F, De Paula JA. GADECCU 2022 Guideline for the treatment of Ulcerative Colitis. Adaptation and updating of the GETECCU 2020 Guideline. Gastroenterol Hepatol. 2023;46 Suppl 1:S1-S56.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 9]  [Reference Citation Analysis (5)]
91.  Gordon H, Minozzi S, Kopylov U, Verstockt B, Chaparro M, Buskens C, Warusavitarne J, Agrawal M, Allocca M, Atreya R, Battat R, Bettenworth D, Bislenghi G, Brown SR, Burisch J, Casanova MJ, Czuber-Dochan W, de Groof J, El-Hussuna A, Ellul P, Fidalgo C, Fiorino G, Gisbert JP, Sabino JG, Hanzel J, Holubar S, Iacucci M, Iqbal N, Kapizioni C, Karmiris K, Kobayashi T, Kotze PG, Luglio G, Maaser C, Moran G, Noor N, Papamichael K, Peros G, Reenaers C, Sica G, Sigall-Boneh R, Vavricka SR, Yanai H, Myrelid P, Adamina M, Raine T. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. J Crohns Colitis. 2024;18:1531-1555.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 300]  [Cited by in RCA: 285]  [Article Influence: 142.5]  [Reference Citation Analysis (19)]
92.  Siegel CA, Sharma D, Griffith J, Doan Q, Xuan S, Malter L. Treatment Pathways in Patients With Crohn's Disease and Ulcerative Colitis: Understanding the Road to Advanced Therapy. Crohns Colitis 360. 2024;6:otae040.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 14]  [Reference Citation Analysis (0)]
93.  Deng Z, Wang S, Wu C, Wang C. IL-17 inhibitor-associated inflammatory bowel disease: A study based on literature and database analysis. Front Pharmacol. 2023;14:1124628.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 27]  [Cited by in RCA: 85]  [Article Influence: 28.3]  [Reference Citation Analysis (0)]
94.  Caron B, Jouzeau JY, Miossec P, Petitpain N, Gillet P, Netter P, Peyrin-Biroulet L. Gastroenterological safety of IL-17 inhibitors: a systematic literature review. Expert Opin Drug Saf. 2022;21:223-239.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 3]  [Cited by in RCA: 29]  [Article Influence: 5.8]  [Reference Citation Analysis (0)]
95.  Noviello D, Mager R, Roda G, Borroni RG, Fiorino G, Vetrano S. The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges. Front Immunol. 2021;12:611256.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 38]  [Cited by in RCA: 118]  [Article Influence: 23.6]  [Reference Citation Analysis (8)]
96.  Ventura U, Ceriani T, Moggio R. Gastric mucosa permeability and HCO3- secretion 'in vivo' during perfusion of damaging and protective agents across canine Heidenhain pouches. Scand J Gastroenterol Suppl. 1984;92:55-58.  [PubMed]  [DOI]
97.  Ono B. [Basic yeast genetic procedures]. Tanpakushitsu Kakusan Koso. 1994;39:760-769.  [PubMed]  [DOI]
98.  Bassolas-Molina H, Raymond E, Labadia M, Wahle J, Ferrer-Picón E, Panzenbeck M, Zheng J, Harcken C, Hughes R, Turner M, Smith D, Calderón-Gómez E, Esteller M, Carrasco A, Esteve M, Dotti I, Corraliza AM, Masamunt MC, Arajol C, Guardiola J, Ricart E, Nabozny G, Salas A. An RORγt Oral Inhibitor Modulates IL-17 Responses in Peripheral Blood and Intestinal Mucosa of Crohn's Disease Patients. Front Immunol. 2018;9:2307.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 26]  [Cited by in RCA: 39]  [Article Influence: 4.9]  [Reference Citation Analysis (4)]
99.  Murgiano M, Bartocci B, Puca P, di Vincenzo F, Del Gaudio A, Papa A, Cammarota G, Gasbarrini A, Scaldaferri F, Lopetuso LR. Gut Microbiota Modulation in IBD: From the Old Paradigm to Revolutionary Tools. Int J Mol Sci. 2025;26:3059.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 20]  [Reference Citation Analysis (2)]
100.  Qiu Y, Li C, Sheng S. Efficacy and safety of stem cell therapy for Crohn's disease: a meta-analysis of randomized controlled trials. Stem Cell Res Ther. 2024;15:28.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 9]  [Reference Citation Analysis (1)]
101.  Wang S, Lei B, Zhang E, Gong P, Gu J, He L, Han L, Yuan Z. Targeted Therapy for Inflammatory Diseases with Mesenchymal Stem Cells and Their Derived Exosomes: From Basic to Clinics. Int J Nanomedicine. 2022;17:1757-1781.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 151]  [Cited by in RCA: 149]  [Article Influence: 37.3]  [Reference Citation Analysis (4)]
102.  Jiang X, Luo X, Cai C, Bai Y, Ding H, Yue H, Li Y, Yang Z, Zhang H, Liang Y, Peng C, Huang H, Liu M, Li Z, Shi Y, Han S, Li X, Zhang B. Umbilical cord mesenchymal stem cells in ulcerative colitis treatment: efficacy and possible mechanisms. Stem Cell Res Ther. 2024;15:272.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 10]  [Cited by in RCA: 12]  [Article Influence: 6.0]  [Reference Citation Analysis (0)]
103.  Mohammadi TC, Jazi K, Bolouriyan A, Soleymanitabar A. Stem cells in treatment of crohn's disease: Recent advances and future directions. Transpl Immunol. 2023;80:101903.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 6]  [Reference Citation Analysis (0)]
104.  Stavely R, Robinson AM, Fraser S, Filippone RT, Stojanovska V, Eri R, Apostolopoulos V, Sakkal S, Nurgali K. Bone marrow-derived mesenchymal stem cells mitigate chronic colitis and enteric neuropathy via anti-inflammatory and anti-oxidative mechanisms. Sci Rep. 2024;14:6649.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 14]  [Cited by in RCA: 13]  [Article Influence: 6.5]  [Reference Citation Analysis (0)]
105.  Shi X, Chen Q, Wang F. Mesenchymal stem cells for the treatment of ulcerative colitis: a systematic review and meta-analysis of experimental and clinical studies. Stem Cell Res Ther. 2019;10:266.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 46]  [Cited by in RCA: 60]  [Article Influence: 8.6]  [Reference Citation Analysis (0)]
106.  Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Leselbaum A, Danese S; ADMIRE CD Study Group Collaborators. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388:1281-1290.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 924]  [Cited by in RCA: 820]  [Article Influence: 82.0]  [Reference Citation Analysis (8)]
107.  Kałużna A, Olczyk P, Komosińska-Vassev K. The Role of Innate and Adaptive Immune Cells in the Pathogenesis and Development of the Inflammatory Response in Ulcerative Colitis. J Clin Med. 2022;11:400.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 172]  [Cited by in RCA: 180]  [Article Influence: 45.0]  [Reference Citation Analysis (6)]
108.  Clough JN, Omer OS, Tasker S, Lord GM, Irving PM. Regulatory T-cell therapy in Crohn's disease: challenges and advances. Gut. 2020;69:942-952.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 96]  [Cited by in RCA: 147]  [Article Influence: 24.5]  [Reference Citation Analysis (2)]
109.  Zhang S, Zhong R, Tang S, Chen L, Zhang H. Metabolic regulation of the Th17/Treg balance in inflammatory bowel disease. Pharmacol Res. 2024;203:107184.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 42]  [Cited by in RCA: 50]  [Article Influence: 25.0]  [Reference Citation Analysis (0)]
110.  Cui Y, David M, Bouchareychas L, Rouquier S, Sajuthi S, Ayrault M, Navarin C, Lara G, Lafon A, Saviane G, Boulakirba S, Menardi A, Demory A, Frikeche J, de la Forest Divonne Beghelli S, Lu HH, Dumont C, Abel T, Fenard D, de la Rosa M, Gertner-Dardenne J. IL23R-Specific CAR Tregs for the Treatment of Crohn's Disease. J Crohns Colitis. 2025;19:jjae135.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 6]  [Cited by in RCA: 34]  [Article Influence: 34.0]  [Reference Citation Analysis (0)]
111.  Neurath MF, Sands BE, Rieder F. Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet? Gut. 2024;74:9-14.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 2]  [Cited by in RCA: 33]  [Article Influence: 16.5]  [Reference Citation Analysis (11)]
112.  Voskens C, Stoica D, Rosenberg M, Vitali F, Zundler S, Ganslmayer M, Knott H, Wiesinger M, Wunder J, Kummer M, Siegmund B, Schnoy E, Rath T, Hartmann A, Hackstein H, Schuler-Thurner B, Berking C, Schuler G, Atreya R, Neurath MF. Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis. Gut. 2023;72:49-53.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 47]  [Cited by in RCA: 83]  [Article Influence: 27.7]  [Reference Citation Analysis (9)]
113.  Alhendi A, Naser SA. The dual role of interleukin-6 in Crohn's disease pathophysiology. Front Immunol. 2023;14:1295230.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 74]  [Cited by in RCA: 71]  [Article Influence: 23.7]  [Reference Citation Analysis (1)]
114.  Zhao H, Ming T, Tang S, Ren S, Yang H, Liu M, Tao Q, Xu H. Wnt signaling in colorectal cancer: pathogenic role and therapeutic target. Mol Cancer. 2022;21:144.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 752]  [Cited by in RCA: 686]  [Article Influence: 171.5]  [Reference Citation Analysis (9)]
115.  Qiu J, Shi W, Zhang J, Gao Q, Feng L, Zhuang Z. Peripheral CD4(+)CD25(hi)CD127(low) regulatory T cells are increased in patients with gastrointestinal cancer. BMC Gastroenterol. 2023;23:168.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 4]  [Reference Citation Analysis (0)]
116.  Bacić D, Uravić M, Bacić R, Sutić I, Petrosić N. Augmentation of regulatory T cells (CD4+CD25+Foxp3+) correlates with tumor stage in patients with colorectal cancer. Coll Antropol. 2011;35 Suppl 2:65-68.  [PubMed]  [DOI]
117.  Ge C, Lu Y, Shen Z, Lu Y, Liu X, Zhang M, Liu Y, Shen H, Zhu L. Machine learning and metabolomics identify biomarkers associated with the disease extent of ulcerative colitis. J Crohns Colitis. 2025;19:jjaf020.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 17]  [Reference Citation Analysis (0)]
118.  Bashiri K, Mattar MC, Meighani A, Mason AL. Peroxisome proliferator-activated receptors in inflammatory bowel disease: linking immunometabolism, lipid signaling, and therapeutic potential. Intest Res. 2026;24:11-26.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 6]  [Reference Citation Analysis (0)]
119.  Faubert B, Vincent EE, Poffenberger MC, Jones RG. The AMP-activated protein kinase (AMPK) and cancer: many faces of a metabolic regulator. Cancer Lett. 2015;356:165-170.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 241]  [Cited by in RCA: 288]  [Article Influence: 24.0]  [Reference Citation Analysis (0)]
120.  Guo B, Han X, Tkach D, Huang SG, Zhang D. AMPK promotes the survival of colorectal cancer stem cells. Animal Model Exp Med. 2018;1:134-142.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 23]  [Cited by in RCA: 27]  [Article Influence: 3.4]  [Reference Citation Analysis (0)]
121.  Kang J, Gallucci S, Pan J, Oakhill JS, Sanij E. The role of STK11/LKB1 in cancer biology: implications for ovarian tumorigenesis and progression. Front Cell Dev Biol. 2024;12:1449543.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 13]  [Reference Citation Analysis (0)]
122.  Alharbi M. AMPK as a Double-Edged sword in cancer: role of natural compounds in its regulation. Nat Prod Res. 2026;1-16.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 2]  [Reference Citation Analysis (0)]
123.  Liu M, Ge J, Guo L, Wu Z, Cheng Z, Liu Z, Liu Y. Integrative machine learning and multi-omics framework identifies shared biomarkers for rheumatoid arthritis and ulcerative colitis. PLoS One. 2025;20:e0336243.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 1]  [Reference Citation Analysis (0)]
124.  Qin L, Lv W. Dietary content and eating behavior in ulcerative colitis: a narrative review and future perspective. Nutr J. 2025;24:12.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1]  [Cited by in RCA: 12]  [Article Influence: 12.0]  [Reference Citation Analysis (0)]
125.  Guo G, Tan Z, Liu Y, Shi F, She J. The therapeutic potential of stem cell-derived exosomes in the ulcerative colitis and colorectal cancer. Stem Cell Res Ther. 2022;13:138.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 114]  [Cited by in RCA: 118]  [Article Influence: 29.5]  [Reference Citation Analysis (1)]
126.  Singh V, Lee G, Son H, Koh H, Kim ES, Unno T, Shin JH. Butyrate producers, "The Sentinel of Gut": Their intestinal significance with and beyond butyrate, and prospective use as microbial therapeutics. Front Microbiol. 2022;13:1103836.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 580]  [Cited by in RCA: 491]  [Article Influence: 163.7]  [Reference Citation Analysis (2)]
127.  Lo Presti A, Del Chierico F, Altomare A, Zorzi F, Monteleone G, Putignani L, Angeletti S, Cicala M, Guarino MPL, Ciccozzi M. Phylogenetic analysis of Prevotella copri from fecal and mucosal microbiota of IBS and IBD patients. Ther Adv Gastroenterol. 2023;16:17562848221136328.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 21]  [Cited by in RCA: 19]  [Article Influence: 6.3]  [Reference Citation Analysis (0)]
128.  Xia S, Ma L, Li H, Li Y, Yu L. Prevalence of enterotoxigenic Bacteroides fragilis in patients with colorectal cancer: a systematic review and meta-analysis. Front Cell Infect Microbiol. 2025;15:1525609.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 17]  [Reference Citation Analysis (0)]
129.  Zhan Z, Liu W, Pan L, Bao Y, Yan Z, Hong L. Overabundance of Veillonella parvula promotes intestinal inflammation by activating macrophages via LPS-TLR4 pathway. Cell Death Discov. 2022;8:251.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 3]  [Cited by in RCA: 88]  [Article Influence: 22.0]  [Reference Citation Analysis (0)]
130.  Vujkovic-Cvijin I, Welles HC, Ha CWY, Huq L, Mistry S, Brenchley JM, Trinchieri G, Devkota S, Belkaid Y. The systemic anti-microbiota IgG repertoire can identify gut bacteria that translocate across gut barrier surfaces. Sci Transl Med. 2022;14:eabl3927.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 61]  [Cited by in RCA: 63]  [Article Influence: 15.8]  [Reference Citation Analysis (4)]
131.  Xiang B, Hu J, Zhang M, Zhi M. The involvement of oral bacteria in inflammatory bowel disease. Gastroenterol Rep (Oxf). 2024;12:goae076.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 13]  [Cited by in RCA: 14]  [Article Influence: 7.0]  [Reference Citation Analysis (0)]
132.  Chen Y, Ma Y, Leng Y, Li X, Qin S, Li X, Zhang Z, Yu H. The mitigative effects of Blautia producta 1009924 on DSS-induced intestinal inflammation. Front Microbiol. 2025;16:1560441.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 2]  [Cited by in RCA: 4]  [Article Influence: 4.0]  [Reference Citation Analysis (0)]
133.  Zheng M, Han R, Yuan Y, Xing Y, Zhang W, Sun Z, Liu Y, Li J, Mao T. The role of Akkermansia muciniphila in inflammatory bowel disease: Current knowledge and perspectives. Front Immunol. 2022;13:1089600.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 88]  [Cited by in RCA: 187]  [Article Influence: 62.3]  [Reference Citation Analysis (3)]
134.  Ma Y, Yang D, Huang J, Liu K, Liu H, Wu H, Bao C. Probiotics for inflammatory bowel disease: Is there sufficient evidence? Open Life Sci. 2024;19:20220821.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 29]  [Reference Citation Analysis (0)]
135.  Li C, Peng K, Xiao S, Long Y, Yu Q. The role of Lactobacillus in inflammatory bowel disease: from actualities to prospects. Cell Death Discov. 2023;9:361.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 153]  [Reference Citation Analysis (0)]
136.  Ervina WF, Madyawati SP, Saputro ID, Safari D, Putri RE, Zulqaida S. A Meta-analysis of the Effect of Probiotic Lactobacillus sp. as Immunomodulating Inflammatory Responses. Medeni Med J. 2024;39:122-131.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 2]  [Reference Citation Analysis (0)]
137.  Fan TJ, Goeser L, Lu K, Faith JJ, Hansen JJ. Enterococcus faecalis Glucosamine Metabolism Exacerbates Experimental Colitis. Cell Mol Gastroenterol Hepatol. 2021;12:1373-1389.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 9]  [Cited by in RCA: 15]  [Article Influence: 3.0]  [Reference Citation Analysis (0)]
138.  Du L, Kim JJ, Shen J, Chen B, Dai N. KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis. Oncotarget. 2017;8:22175-22186.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 30]  [Cited by in RCA: 58]  [Article Influence: 6.4]  [Reference Citation Analysis (0)]
139.  Kobayashi K, Tomita H, Shimizu M, Tanaka T, Suzui N, Miyazaki T, Hara A. p53 Expression as a Diagnostic Biomarker in Ulcerative Colitis-Associated Cancer. Int J Mol Sci. 2017;18:1284.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 28]  [Cited by in RCA: 50]  [Article Influence: 5.6]  [Reference Citation Analysis (0)]
140.  Yaeger R, Shah MA, Miller VA, Kelsen JR, Wang K, Heins ZJ, Ross JS, He Y, Sanford E, Yantiss RK, Balasubramanian S, Stephens PJ, Schultz N, Oren M, Tang L, Kelsen D. Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease. Gastroenterology. 2016;151:278-287.e6.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 175]  [Cited by in RCA: 170]  [Article Influence: 17.0]  [Reference Citation Analysis (5)]
141.  Moriyama T, Matsumoto T, Nakamura S, Jo Y, Mibu R, Yao T, Iida M. Hypermethylation of p14 (ARF) may be predictive of colitic cancer in patients with ulcerative colitis. Dis Colon Rectum. 2007;50:1384-1392.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 39]  [Cited by in RCA: 35]  [Article Influence: 1.8]  [Reference Citation Analysis (0)]
142.  Wang FY, Arisawa T, Tahara T, Takahama K, Watanabe M, Hirata I, Nakano H. Aberrant DNA methylation in ulcerative colitis without neoplasia. Hepatogastroenterology. 2008;55:62-65.  [PubMed]  [DOI]
143.  Hisamatsu T, Watanabe M, Ogata H, Ezaki T, Hozawa S, Ishii H, Kanai T, Hibi T. Interferon-inducible gene family 1-8U expression in colitis-associated colon cancer and severely inflamed mucosa in ulcerative colitis. Cancer Res. 1999;59:5927-5931.  [PubMed]  [DOI]
144.  Markov AV, Savin IA, Zenkova MA, Sen'kova AV. Identification of Novel Core Genes Involved in Malignant Transformation of Inflamed Colon Tissue Using a Computational Biology Approach and Verification in Murine Models. Int J Mol Sci. 2023;24:4311.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 10]  [Reference Citation Analysis (0)]
145.  Salk JJ, Bansal A, Lai LA, Crispin DA, Ussakli CH, Horwitz MS, Bronner MP, Brentnall TA, Loeb LA, Rabinovitch PS, Risques RA. Clonal expansions and short telomeres are associated with neoplasia in early-onset, but not late-onset, ulcerative colitis. Inflamm Bowel Dis. 2013;19:2593-2602.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 19]  [Cited by in RCA: 28]  [Article Influence: 2.2]  [Reference Citation Analysis (2)]
146.  Baker KT, Salk JJ, Brentnall TA, Risques RA. Precancer in ulcerative colitis: the role of the field effect and its clinical implications. Carcinogenesis. 2018;39:11-20.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 8]  [Cited by in RCA: 26]  [Article Influence: 3.3]  [Reference Citation Analysis (4)]
147.  East JE, Gordon M, Nigam GB, Sinopoulou V, Bateman AC, Din S, Iacucci M, Kabir M, Lamb CA, Wilson A, Al Bakir I, Dhar A, Dolwani S, Faiz O, Hart A, Hayee B, Healey C, Leedham SJ, Novelli MR, Raine T, Rutter MD, Shepherd NA, Subramanian V, Vance M, Wakeman R, White L, Trudgill NJ, Morris AJ. British Society of Gastroenterology guidelines on colorectal surveillance in inflammatory bowel disease. Gut. 2025;75:e335023.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 29]  [Cited by in RCA: 33]  [Article Influence: 33.0]  [Reference Citation Analysis (0)]
148.  Lu H, Hu X, Chen Y, He J. Colorectal cancer in ulcerative colitis: unraveling mechanisms and advancing surveillance and chemoprevention. Front Oncol. 2026;16:1793470.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 2]  [Cited by in RCA: 1]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
149.  Al Bakir I, Curtius K, Cresswell GD, Grant HE, Nasreddin N, Smith K, Nowinski S, Guo Q, Belnoue-Davis HL, Fisher J, Clarke T, Kimberley C, Mossner M, Dunne PD, Loughrey MB, Speight A, East JE, Wright NA, Rodriguez-Justo M, Jansen M, Moorghen M, Baker AM, Leedham SJ, Hart AL, Graham TA. Low-coverage whole genome sequencing of low-grade dysplasia strongly predicts advanced neoplasia risk in ulcerative colitis. Gut. 2025;74:740-751.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 9]  [Cited by in RCA: 10]  [Article Influence: 10.0]  [Reference Citation Analysis (0)]
150.  Kapadia A, Joshi D, Chavda A, Bhatt P. From inflammation to carcinogenesis: Distinct pathways and clinical implications of IBD-associated colorectal cancer compared with sporadic CRC. Pathol Res Pract. 2025;275:156249.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 12]  [Reference Citation Analysis (11)]
151.  Toiyama Y, Okugawa Y, Tanaka K, Araki T, Uchida K, Hishida A, Uchino M, Ikeuchi H, Hirota S, Kusunoki M, Boland CR, Goel A. A Panel of Methylated MicroRNA Biomarkers for Identifying High-Risk Patients With Ulcerative Colitis-Associated Colorectal Cancer. Gastroenterology. 2017;153:1634-1646.e8.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 38]  [Cited by in RCA: 42]  [Article Influence: 4.7]  [Reference Citation Analysis (0)]
152.  Włodarczyk M, Maryńczak K, Burzyński J, Włodarczyk J, Basak J, Fichna J, Majsterek I, Ciesielski P, Spinelli A, Dziki Ł. The role of miRNAs in the pathogenesis, diagnosis, and treatment of colorectal cancer and colitis-associated cancer. Clin Exp Med. 2025;25:86.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 8]  [Cited by in RCA: 14]  [Article Influence: 14.0]  [Reference Citation Analysis (8)]
153.  Beggs AD, Mehta S, Deeks JJ, James JD, Caldwell GM, Dilworth MP, Stockton JD, Blakeway D, Pestinger V, Vince A, Taniere P, Iqbal T, Magill L, Matthews G, Morton DG; ENDCAP-C Module 1 Collaborative. Validation of epigenetic markers to identify colitis associated cancer: Results of module 1 of the ENDCAP-C study. EBioMedicine. 2019;39:265-271.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 7]  [Cited by in RCA: 17]  [Article Influence: 2.4]  [Reference Citation Analysis (0)]
154.  Ganesh N, Grady WM, Kaz AM. Epigenetic Alterations in Colitis-Associated Colorectal Cancer. Epigenomes. 2026;10:4.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 4]  [Reference Citation Analysis (0)]
155.  Ghavami SB, Moshiri A, Bonaretti C, Farmani M, Squillario M, Di Marco E, Shahrokh S, Balaii H, Corrias MV, Ponzoni M, Sadeghi A, Biassoni R. Predictive Microbial Markers Distinguish Responders and Non-Responders to Adalimumab: A Step Toward Precision Medicine in Ulcerative Colitis. Microorganisms. 2025;13:1941.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 3]  [Cited by in RCA: 6]  [Article Influence: 6.0]  [Reference Citation Analysis (0)]
156.  Cui Y. Assessment of the relationship between gut microbiota, inflammatory markers, and colorectal cancer. Front Cell Infect Microbiol. 2025;15:1604651.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 3]  [Cited by in RCA: 5]  [Article Influence: 5.0]  [Reference Citation Analysis (0)]
157.  Champney MS, Bressler A, Domino DJ. Incidental finding of lymphogranuloma venereum at the time of inguinal herniorrhaphy. Am Surg. 2011;77:247-248.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 29]  [Cited by in RCA: 26]  [Article Influence: 1.7]  [Reference Citation Analysis (0)]
158.  Xie H, Xiao SY, Pai R, Jiang W, Shadrach B, Carver P, Wang Y, Shen B, Zhou W, Liu X. Diagnostic utility of TP53 and cytokeratin 7 immunohistochemistry in idiopathic inflammatory bowel disease-associated neoplasia. Mod Pathol. 2014;27:303-313.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 21]  [Cited by in RCA: 26]  [Article Influence: 2.2]  [Reference Citation Analysis (0)]
159.  Radović S, Selak I, Babić M, Vukobrat-Bijedić Z, Knezević Z. Anti-cytokeratin 7: a positive marker for epithelial dysplasia in flat bowel mucosa. Bosn J Basic Med Sci. 2004;4:24-30.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 3]  [Cited by in RCA: 6]  [Article Influence: 0.3]  [Reference Citation Analysis (0)]
160.  Feng X, Wang H, Ye S, Guan J, Tan W, Cheng S, Wei G, Wu W, Wu F, Zhou Y. Up-regulation of microRNA-126 may contribute to pathogenesis of ulcerative colitis via regulating NF-kappaB inhibitor IκBα. PLoS One. 2012;7:e52782.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 112]  [Cited by in RCA: 107]  [Article Influence: 7.6]  [Reference Citation Analysis (4)]
161.  Ždralević M, Radović A, Raonić J, Popovic N, Klisic A, Vučković L. Advances in microRNAs as Emerging Biomarkers for Colorectal Cancer Early Detection and Diagnosis. Int J Mol Sci. 2024;25:11060.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 5]  [Cited by in RCA: 17]  [Article Influence: 8.5]  [Reference Citation Analysis (0)]
162.  Fasseu M, Tréton X, Guichard C, Pedruzzi E, Cazals-Hatem D, Richard C, Aparicio T, Daniel F, Soulé JC, Moreau R, Bouhnik Y, Laburthe M, Groyer A, Ogier-Denis E. Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease. PLoS One. 2010;5:e13160.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 227]  [Cited by in RCA: 230]  [Article Influence: 14.4]  [Reference Citation Analysis (5)]
163.  Quintanilla I, Jung G, Jimeno M, Lozano JJ, Sidorova J, Camps J, Carballal S, Bujanda L, Vera MI, Quintero E, Carrillo-Palau M, Cuatrecasas M, Castells A, Panés J, Ricart E, Moreira L, Balaguer F, Pellisé M. Differentially Deregulated MicroRNAs as Novel Biomarkers for Neoplastic Progression in Ulcerative Colitis. Clin Transl Gastroenterol. 2022;13:e00489.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 5]  [Cited by in RCA: 9]  [Article Influence: 2.3]  [Reference Citation Analysis (0)]
164.  Danardono E, Soediono MR, Amiruddin MTA. Role of Liquid Biopsy as a Future Approach to Early Diagnosis and Management of Colorectal Cancer. Indones J Cancer. 2025;19:465-470.  [PubMed]  [DOI]  [Full Text]
165.  Kakiuchi N, Yoshida K, Uchino M, Kihara T, Akaki K, Inoue Y, Kawada K, Nagayama S, Yokoyama A, Yamamoto S, Matsuura M, Horimatsu T, Hirano T, Goto N, Takeuchi Y, Ochi Y, Shiozawa Y, Kogure Y, Watatani Y, Fujii Y, Kim SK, Kon A, Kataoka K, Yoshizato T, Nakagawa MM, Yoda A, Nanya Y, Makishima H, Shiraishi Y, Chiba K, Tanaka H, Sanada M, Sugihara E, Sato TA, Maruyama T, Miyoshi H, Taketo MM, Oishi J, Inagaki R, Ueda Y, Okamoto S, Okajima H, Sakai Y, Sakurai T, Haga H, Hirota S, Ikeuchi H, Nakase H, Marusawa H, Chiba T, Takeuchi O, Miyano S, Seno H, Ogawa S. Frequent mutations that converge on the NFKBIZ pathway in ulcerative colitis. Nature. 2020;577:260-265.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 100]  [Cited by in RCA: 212]  [Article Influence: 30.3]  [Reference Citation Analysis (6)]
166.  Zhou RW, Harpaz N, Itzkowitz SH, Parsons RE. Molecular mechanisms in colitis-associated colorectal cancer. Oncogenesis. 2023;12:48.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 116]  [Cited by in RCA: 97]  [Article Influence: 32.3]  [Reference Citation Analysis (4)]
167.  Zhao X, Zhou C, Ma J, Zhu Y, Sun M, Wang P, Zhang Y, Ma H, Zhang H. Efficacy and safety of rectal 5-aminosalicylic acid versus corticosteroids in active distal ulcerative colitis: a systematic review and network meta-analysis. Sci Rep. 2017;7:46693.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 11]  [Cited by in RCA: 13]  [Article Influence: 1.4]  [Reference Citation Analysis (0)]
168.  Arzivian A, Rubin DT, Seow CH, Kerkham A, Tran Y, Leong RW. The Risk of Relapse Associated With Discontinuation of 5-Aminosalicylates in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Inflamm Bowel Dis. 2026;32:661-676.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 1]  [Reference Citation Analysis (0)]
169.  Dubois-Camacho K, Ottum PA, Franco-Muñoz D, De la Fuente M, Torres-Riquelme A, Díaz-Jiménez D, Olivares-Morales M, Astudillo G, Quera R, Hermoso MA. Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology. World J Gastroenterol. 2017;23:6628-6638.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in CrossRef: 130]  [Cited by in RCA: 110]  [Article Influence: 12.2]  [Reference Citation Analysis (0)]
170.  Quera R, Núñez P, Sicilia B, Flores L, Gomollón F. Corticosteroids in inflammatory bowel disease: Are they still a therapeutic option? Gastroenterol Hepatol. 2023;46:716-726.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 3]  [Cited by in RCA: 12]  [Article Influence: 4.0]  [Reference Citation Analysis (0)]
171.  Neurath M. Thiopurines in IBD: What Is Their Mechanism of Action? Gastroenterol Hepatol (N Y). 2010;6:435-436.  [PubMed]  [DOI]
172.  Bauer R. Perturbed angular correlation spectroscopy and its application to metal sites in proteins: possibilities and limitations. Q Rev Biophys. 1985;18:1-64.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 50]  [Cited by in RCA: 37]  [Article Influence: 0.9]  [Reference Citation Analysis (0)]
173.  Mallick B, Malik S. Use of Azathioprine in Ulcerative Colitis: A Comprehensive Review. Cureus. 2022;14:e24874.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 11]  [Reference Citation Analysis (0)]
174.  Qian X, Wang T, Shen J, Ran Z. Low dose of azathioprine is effective to induce and maintain remission in active Crohn disease: A prospective observational study. Medicine (Baltimore). 2018;97:e11814.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 11]  [Cited by in RCA: 12]  [Article Influence: 1.5]  [Reference Citation Analysis (1)]
175.  Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol. 2004;2:731-743.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 201]  [Cited by in RCA: 182]  [Article Influence: 8.3]  [Reference Citation Analysis (4)]
176.  Goldstein ES, Marion JF, Present DH. 6-Mercaptopurine is effective in Crohn's disease without concomitant steroids. Inflamm Bowel Dis. 2004;10:79-84.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 15]  [Cited by in RCA: 14]  [Article Influence: 0.6]  [Reference Citation Analysis (0)]
177.  Sequier L, Caron B, Loeuille D, Honap S, Jairath V, Netter P, Danese S, Sibilia J, Peyrin-Biroulet L. Systematic review: Methotrexate-A poorly understood and underused medication in inflammatory bowel disease. Aliment Pharmacol Ther. 2024;60:686-700.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 15]  [Cited by in RCA: 14]  [Article Influence: 7.0]  [Reference Citation Analysis (1)]
178.  AlAmeel T, Al Sulais E, Raine T. Methotrexate in inflammatory bowel disease: A primer for gastroenterologists. Saudi J Gastroenterol. 2022;28:250-260.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 6]  [Cited by in RCA: 12]  [Article Influence: 3.0]  [Reference Citation Analysis (0)]
179.  Rampton DS. Methotrexate in Crohn's disease. Gut. 2001;48:790-791.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 23]  [Cited by in RCA: 24]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
180.  Samaan M, Campbell S, Cunningham G, Tamilarasan AG, Irving PM, McCartney S. Biologic therapies for Crohn's disease: optimising the old and maximising the new. F1000Res. 2019;8:F1000 Faculty Rev-F1000 Faculty1210.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 15]  [Cited by in RCA: 29]  [Article Influence: 4.1]  [Reference Citation Analysis (1)]
181.  Parsi MA, Achkar JP, Richardson S, Katz J, Hammel JP, Lashner BA, Brzezinski A. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology. 2002;123:707-713.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 210]  [Cited by in RCA: 180]  [Article Influence: 7.5]  [Reference Citation Analysis (0)]
182.  Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results. Gastroenterol Hepatol (N Y). 2013;9:317-320.  [PubMed]  [DOI]
183.  Ballanger P, Breilh D, Mage P, Ballanger R. [Diagnostic and therapeutic approach to the extension of kidney cancer to the vena cava]. Ann Urol (Paris). 1986;20:280-285.  [PubMed]  [DOI]
184.  Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C; UNIFI Study Group. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2019;381:1201-1214.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1077]  [Cited by in RCA: 999]  [Article Influence: 142.7]  [Reference Citation Analysis (6)]
185.  Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel JF, Parkes G, Peyrin-Biroulet L, D'Haens G, Hisamatsu T, Siegmund B, Wu K, Boland BS, Melmed GY, Armuzzi A, Levine P, Kalabic J, Chen S, Cheng L, Shu L, Duan WR, Pivorunas V, Sanchez Gonzalez Y, D'Cunha R, Neimark E, Wallace K, Atreya R, Ferrante M, Loftus EV Jr; INSPIRE and COMMAND Study Group. Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials. JAMA. 2024;332:881-897.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 103]  [Cited by in RCA: 116]  [Article Influence: 58.0]  [Reference Citation Analysis (37)]
186.  Crooks B, Barnes T, Limdi JK. Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms. Drugs Context. 2020;9:2019-10.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 10]  [Cited by in RCA: 17]  [Article Influence: 2.8]  [Reference Citation Analysis (0)]
187.  Özdoğan O, Yaraş S. Upadacitinib in Biologic-Experienced Inflammatory Bowel Disease: Real-World Efficacy, Safety, and Laboratory Outcomes. Medicina (Kaunas). 2025;61:1692.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 4]  [Reference Citation Analysis (2)]
188.  Loftus EV Jr, Panés J, Lacerda AP, Peyrin-Biroulet L, D'Haens G, Panaccione R, Reinisch W, Louis E, Chen M, Nakase H, Begun J, Boland BS, Phillips C, Mohamed MF, Liu J, Geng Z, Feng T, Dubcenco E, Colombel JF. Upadacitinib Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2023;388:1966-1980.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 381]  [Cited by in RCA: 388]  [Article Influence: 129.3]  [Reference Citation Analysis (18)]
189.  Odah T, Karime C, Desai A, Picco MF, Kinnucan JA, Hashash JG, Farraye FA. Response to Upadacitinib in Patients with Inflammatory Bowel Disease Previously Treated with Tofacitinib. Dig Dis Sci. 2024;69:3911-3919.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 13]  [Reference Citation Analysis (0)]
190.  Danese S, Grisham M, Hodge J, Telliez JB. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol. 2016;310:G155-G162.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 154]  [Cited by in RCA: 146]  [Article Influence: 14.6]  [Reference Citation Analysis (17)]
191.  Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, Niezychowski W; Study A3921063 Investigators. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367:616-624.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 693]  [Cited by in RCA: 647]  [Article Influence: 46.2]  [Reference Citation Analysis (9)]
Footnotes

Peer review: Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Oncology

Country of origin: Mexico

Peer-review report’s classification

Scientific quality: Grade B, Grade B, Grade C

Novelty: Grade B, Grade C, Grade C

Creativity or innovation: Grade C, Grade C, Grade C

Scientific significance: Grade B, Grade B, Grade C

P-Reviewer: Gao QQ, PhD, Professor, China; Ke MH, MD, PhD, Professor, China S-Editor: Bai Y L-Editor: A P-Editor: Lei YY

Write to the Help Desk